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A B S T R A C T
Background
Viral infections cause significant morbidity and mortality in patients with hematological malignancies. It remains uncertain whether
viral vaccinations in these patients are supported by good evidence.
Objectives
We aimed to determine the effectiveness and safety of viral vaccines in patients with hematological malignancies.
Search methods
We searched Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL (June 2010), reference
lists of relevant papers, abstracts from scientific meetings and contacted vaccine manufacturers.
Selection criteria
Randomized controlled trials (RCTs) evaluating viral vaccines in patients with hematological malignancies were included.
Data collection and analysis
Relative risk (RR) was used for binary data andmean difference (MD) for continuous data. Primary outcome was incidence of infection.
Secondary outcomes weremortality, incidence of complications and severe viral infection, hospitalization, immune response and adverse
effects. Fixed-effect model was used in meta-analyses.
Main results
Eight RCTs were included, with 305 patients in the intervention groups and 288 in the control groups. They evaluated heat-inactivated
varicella zoster virus (VZV) vaccine (two trials), influenza vaccines (five trials) and inactivated poliovirus vaccine (IPV) (one trial).
Seven trials had high and one trial had moderate risk of bias.
VZV vaccine might reduce herpes zoster compared to no vaccine (RR 0.54, 95% CI 0.3 to 1.0, P=0.05), but not statistically significant.
Vaccination also demonstrated efficacy in immune response but frequently caused local adverse effects. One trial reported severity score
of zoster, which favored vaccination (MD 2.6, 95% CI 0.94 to 4.26, P=0.002).
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Two RCTs compared inactivated influenza vaccine with no vaccine and reported lower risk of lower respiratory infections (RR 0.39,
95% CI 0.19 to 0.78, P=0.008) and hospitalization (RR 0.17, 95% CI 0.09 to 0.31, P<0.00001) in vaccine recipients. However,
vaccine recipients more frequently experienced irritability and local adverse effects. There was no significant difference in seroconversion
between one and two doses of influenza vaccine (one trial), or between recombinant and standard influenza vaccine (one trial), or
influenza vaccine given with or without re-induction chemotherapy (one trial).
The IPV trial comparing vaccination starting at 6 versus 18 months after stem cell transplant (SCT) found no significant difference in
seroconversion.
Authors’ conclusions
Inactivated VZV vaccine might reduce zoster severity in adult SCT recipients. Inactivated influenza vaccine might reduce respiratory
infections and hospitalization in adults with multiple myeloma or children with leukemia or lymphoma. However, the quality of
evidence is low. Local adverse effects occur frequently. Further high-quality RCTs are needed.
P L A I N L A N G U A G E S U M M A R Y
Varicella and influenza vaccines may reduce morbidity in patients with blood cancers
Viral infections cause significant disease and even death in patients with blood cancers. In the current systematic review of randomized
controlled trials (RCTs) we aimed to evaluate the efficacy and safety of viral vaccines in these patients. The pre-defined primary outcome
was incidence of the infection concerned. Secondary outcomes weremortality due to the viral infection, all-cause mortality, incidence of
complications, incidence of severe viral infection, hospitalization rate, in vitro immune response and frequency of adverse effects. Eight
RCTs were included. They evaluated heat-inactivated varicella zoster virus (VZV) vaccine (two trials), influenza vaccines (five trials) and
inactivated poliovirus vaccine (one trial). There were no RCTs on other viral vaccines (hepatitis A, hepatitis B, measles, mumps, rubella).
Only the two trials on VZV vaccine reported our pre-defined primary outcome. All trials reported some of the pre-defined secondary
outcomes. We found that inactivated VZV vaccine might reduce the severity of herpes zoster when given before and after stem cell
transplant in adults with lymphoma or leukemia. Inactivated influenza vaccine might reduce upper and lower respiratory infections and
hospitalization in adults with multiple myeloma who are undergoing chemotherapy, or children with leukemia or lymphoma within
two years post-chemotherapy. However, the quality of evidence is not high. Local adverse effects occur frequently with the vaccines,
although serious adverse effects appear uncommon. Further high-quality RCTs are needed to clarify the benefits and optimal regimens
of viral vaccines for patients with blood cancers.
B A C K G R O U N D
Description of the condition
Viral infections are important causes of morbidity or even mortal-
ity in patients with hematological malignancies who are immuno-
compromised. In addition, viral infections may delay chemother-
apy and necessitate hospitalization and antibiotic administration
(Feldman 1977; Elting 1995; Yousuf 1997).
Description of the intervention
Some viral infections can be prevented by vaccinations, such as
influenza, varicella and herpes zoster. However, the practice of
viral vaccination in patients with hematological malignancies is
highly variable among different treatment centres. It is generally
held that patients with hematological malignancies have altered
immune function, either as a result of the underlying hematologi-
cal malignancy or treatment with chemotherapy; and vaccination
in these patients might be ineffective. In addition, there is often
a concern that vaccination in patients with hematological malig-
nancies might be associated with more adverse effects (Henning
1997; Irish 1998; Booth 2000), especially in the case of live-at-
tenuated vaccines.
American and British guidelines recommend annual vaccination
against influenza for adults and children who are immunosup-
pressed because of disease or treatment (DOH1996; ACIP 2005).
However, there is no clear-cut recommendation as to whether and
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when patients with hematological malignancies should receive in-
fluenza vaccination. A recent study indicated that one-third of
pediatric oncologists and hematologists did not routinely recom-
mend yearly influenza vaccination for children with cancer (Porter
2003).
As modern influenza vaccines contain hemagglutinin and neu-
raminidase surface antigens obtained from chemically inactivated
influenza virus strains, there is no risk of introducing active in-
fection in immunocompromised individuals. Many studies have
documented seroconversion in patients with hematological ma-
lignancies on chemotherapy (Feery 1977; Ortbals 1977; Sumaya
1977; Ganz 1978; Smithson 1978; Hodges 1979; Lange 1979;
Shildt 1979; Sumaya 1982; Engelhard 1993; Lo 1993; Gribabis
1994; Jackowska 1996; Brydak 1997; Brydak 1998; Brydak 1999;
Robertson 2000; Chisholm 2001; Hsieh 2002; Nordoy 2002;
Rapezzi 2003; Porter 2004; Brydak 2006) but other studies did
not reveal sufficient immune response in patients with cancer
(Borella 1971; Allison 1977; Gross 1978; Stiver 1978; Schafer
1979; Steinherz 1980; Brown 1982; Robertson 2000; van der
Velden 2001; Matsuzaki 2005; Mazza 2005). Although the rate of
seroconversion is generally lower than in healthy adult volunteers,
the use of multiple doses of influenza vaccine may increase the
antibody response (Feery 1977; Gribabis 1994). Influenza vacci-
nation is generally safe, with only mild adverse effects, as found in
patients with chronic lymphocytic leukemia or multiple myeloma
(Gribabis 1994; Rapezzi 2003).
Many case series have documented seroconversion in large propor-
tions of leukemic patients who received live-attenuated varicella
vaccine (Hattori 1976; Nakagawa 1978; Brunell 1982; Brunell
1984; Gershon 1984; Kamiya 1984; Konno 1984; Oka 1984;
Austgulen 1985;Gershon 1985;Haas 1985;Heller 1985; Slordahl
1985; Gershon 1989; Arbeter 1990; Gershon 1990; Bancillon
1991; Yeung 1992; Ecevit 1996; LaRussa 1996; Lou 1996;Navajas
1999; Leung 2004) mostly after chemotherapy or during main-
tenance chemotherapy. Protective efficacy may last for at least a
few years (Torigoe 1981; Oka 1984; Gershon 1989). In addition,
leukemic patients who receive the live-attenuated varicella vac-
cine might have lower incidence of zoster than patients who have
natural varicella infections (Hardy 1991; LaRussa 1996; Navajas
1999). Inactivated varicella vaccines might also reduce the risk of
zoster in recipients of an hematopoietic stem cell transplant (Hata
2002). Adverse effects of varicella vaccine are usually mild but vari-
cella or herpes zoster caused by the vaccine virus strain can occur
(Ninane 1985; Christensen 1999).
Measles, mumps, rubella and oral poliomyelitis vaccines are live-
attenuated vaccines given routinely in early childhood in many
countries. However, loss of antibodies has been demonstrated in
patients with hematological malignancies (Bosu 1975; Feldman
1998;Nilsson2000;Nilsson2002;Reinhardt 2003;Zignol 2004).
Re-vaccination has been an important consideration in this group
of patients but the safety and efficacy of re-vaccination in these pa-
tients are not entirely certain (Mitus 1962; Stiehm 1966; Torigoe
1981; Nilsson 2002; Reinhardt 2003). These vaccines are con-
sidered to be contraindicated in patients receiving chemotherapy
because of risks of infection with the vaccine strains. Neverthe-
less, a study found that when measles vaccine was given three to
six months after chemotherapy in leukemic patients, the patients
might still develop protective antibodies though the seropositivity
rate was lower than in healthy controls (Ercan 2005).
A study demonstrated that 85% of leukemic patients who received
hepatitis B vaccine after chemotherapy developed protective an-
tibodies (Fioredda 2005); and one-third of the leukemic children
undergoing maintenance chemotherapy responded to the vaccine
(Yetgin 2001). However, during intensive chemotherapy the sero-
logical response was reported to be very low (Moryl 2004); passive
immunization in the aggressive phase followed by active immu-
nization after cessation of intense chemotherapy might increase
the rates of protective antibody levels (Somjee 2002).
Why it is important to do this review
Although available viral vaccines are shown to be effective in
healthy children for prevention of the respective viral infections,
it is uncertain whether existing evidence is rigorous enough to
show that the vaccines are also effective and safe in patients with
hematological malignancies. These patients are immunocompro-
mised as a result of their diseases or the treatments. Therefore we
examined the efficacy and safety of viral vaccines in patients with
hematological malignancies in a systematic review of randomized
controlled trials.
O B J E C T I V E S
The objectives of this systematic review were to determine the ef-
fectiveness and safety of viral vaccines in patients with hematolog-
ical malignancies:
1. whether viral vaccines are effective in preventing viral
infections in patients with hematological malignancies;
2. whether viral vaccines are effective in preventing
complications or mortality associated with viral infections, or
reduction in severity of the viral infections, in patients with
hematological malignancies;
3. whether a particular type of vaccine or dosing schedule is
more effective than others in patients with hematological
malignancies;
4. whether viral vaccines administered to patients with
hematological malignancies are associated with adverse effects.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) were included in the review.
Types of participants
Patients of all ages with hematological malignancies, including
acute and chronic leukemias, lymphomas (Hodgkin’s and non-
Hodgkin’s) and myelomas, were included.
Types of interventions
Trials evaluating all forms of viral vaccines, including influenza,
varicella, hepatitis A, hepatitis B, measles, mumps, rubella, and
poliomyelitis, were included in the review. The control interven-
tions could be placebo vaccine, no vaccine or an alternative form
of vaccine; or alternative dosing regimens or schedules.
Types of outcome measures
Primary outcomes
Incidence of the viral infection concerned
Secondary outcomes
• Mortality due to the viral infection
• All-cause mortality
• Incidence of complications due to the viral infection
• Incidence of severe viral infection
• Rate of hospitalization due to the viral infection
• In vitro immune response to the vaccine (titre of protective
antibodies, T-cell proliferation)
• Frequency of systemic and local adverse effects
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (The Cochrane Library June 2010), MEDLINE
(1966 toDec 2009), EMBASE (1980 toDec 2009) and CINAHL
(1982 to Dec 2009).
The search strategies for the different electronic databases (using
a combination of controlled vocabulary and text word terms) are
provided in the appendices (Appendix 1, Appendix 2, Appendix
3, Appendix 4).
The reference lists of all relevant papers were searched for further
studies. Other internet sources were also explored:
• NHS National Research Register (www.update-
software.com/national);
• NIH Clinical Trials Database (www.clinicaltrials.gov);
• Meta-register of Clinical Trials (www.controlled-trials.com);
• Digital Dissertations website (www.lib.umi.com/
dissertations);
• Vaccine Adverse Event Reporting System website
(www.vaers.org).
Searching other resources
We also handsearched abstracts from the meetings of the Ameri-
can Society of Hematology (ASH), American Society for Clinical
Oncology (ASCO), European Haematology Association (EHA)
and European Society for Medical Oncology (ESMO) (1993 to
2009).
Articles published only in abstract form would also be included if
authors could be contacted to provide essential details for appraisal
and analysis. The process of searching many different sources
might bring to light direct or indirect references to unpublished
studies. We would seek to obtain copies of such unpublished ma-
terial. In addition, we contacted colleagues and experts in the field
to ascertain any unpublished or ongoing studies. Vaccine manu-
facturers listed at theWorld HealthOrganization (WHO)website
were also contacted.
There was no language restriction in the search and inclusion of
studies. However, multiple publications reporting the same group
of patients or subsets of the group would be excluded.
Data collection and analysis
Selection of studies
Two authors (first and second authors) independently reviewed
titles and abstracts of references retrieved from the searches and se-
lected all potentially relevant studies. Copies of these articles were
obtained and reviewed independently by the same authors against
our pre-defined inclusion criteria. Authors were not blinded to the
names of the trial authors, institutions or journal of publication.
All disagreements about selection of studies were resolved by con-
sensus.
Data extraction and management
Two authors (first and second authors) independently extracted
data from included trials. All disagreements were resolved by con-
sensus. The following data were extracted, when available.
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1. Study methods
i) Design (e.g. randomized or non-randomized)
ii) Randomization method (including list generation)
iii) Method of allocation concealment
iv) Blinding method
v) Stratification factors
2. Participants
i) Inclusion and exclusion criteria
ii) Number (total, per group)
iii) Age and gender distribution
iv) Underlying hematological malignancies
v) Treatments for the underlying hematological
malignancies (chemotherapy, autologous stem cell transplant,
allogeneic stem cell transplant)
vi) Phase of treatments (e.g., before chemotherapy, during
intensive chemotherapy, during maintenance chemotherapy,
post-therapy)
vii) Previous vaccine history
viii) Baseline antibody levels
3. Intervention and control
i) Type of vaccine
ii) Type of control
iii) Details of vaccine administration including dosage
and schedules
iv) Details of co-interventions
4. Follow-up data
i) Duration of follow up
ii) Loss to follow up
5. Outcome data as described above
6. Analysis data
i) Methods of analysis (intention-to-treat or per protocol
analysis)
ii) Comparability of groups at baseline (yes or no)
iii) Statistical techniques
The data were entered into Review Manager (RevMan) by one
author and then checked by the other authors. Since adverse events
are rarely adequately dealtwith by controlled clinical trials, because
the numbers are small and follow up too short, adverse events
would be discussed by taking into account the non-trial literature.
Assessment of risk of bias in included studies
Two authors (first and second authors) independently assessed the
quality of each eligible trial. All disagreements were resolved by
consensus.
The following items were included to assess the methodological
quality of RCTs.
(1) Selection bias, allocation concealment
A. Yes: use of randomization method that did not allow investi-
gator and participant to know or influence the allocation of treat-
ment before eligible participants entered the study.
B. Unclear: randomization stated but no information on method
used was available.
C. No: use of alternate medical record numbers or unsealed en-
velopes as randomization method, or there was information in the
study indicating that investigators or participants could have in-
fluenced the allocation of treatment.
(2) Performance bias
Blinding of care providers: Yes, No, Unclear.
Blinding of participants: Yes, No, Unclear.
Care providers and patients were considered not blinded if the
intervention group could be identified in > 20% of participants
because of the side effects of treatment.
(3) Detection bias
Blinding of outcome assessors: Yes, No, Unclear.
(4) Attrition bias, intention-to-treat analysis
A. Yes: all participants were analysed in the treatment group to
which they were allocated, regardless of whether of not they re-
ceived the allocated intervention.
B. No: some participants were not analysed in the treatment group
to which they were randomized because they did not receive study
intervention or because of protocol violation.
C. Unclear: inability to determine if patients were analysed ac-
cording to the intention-to-treat principle after contact with the
authors.
We summarized the quality of a trial into one of three categories.
A. Low risk of bias: all the validity criteria met.
B. Moderate risk of bias: one or more validity criteria partly met
but none not met.
C. High risk of bias: one or more criteria not met.
Measures of treatment effect
Relative risk (RR) estimations with 95% confidence intervals
(CI) were used for binary outcomes. Weighted mean difference
(WMD) estimations with 95% CI were used for continuous out-
comes. All analyses included all participants in the treatment
groups to which they were allocated (intention-to-treat analysis).
Dealing with missing data
The authors of included studies were contacted to supply missing
data.Missing data and drop-outs or attrition were assessed for each
included study and the extent to which the results and conclusions
of the review could be altered by themissing data were assessed and
discussed. If less than 70% of patients allocated to the treatments
were reported on at the end of the trial, for a particular outcome,
those data were considered to be prone to bias.
Assessment of heterogeneity
Clinical heterogeneity were assessed by comparing the distribu-
tion of important participant factors between trials (age, under-
lying hematological malignancy, phase of treatment), and trial
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factors (randomization concealment, blinding of outcome assess-
ment, losses to follow up, vaccine regimens). Statistical hetero-
geneity was assessed by examining the I2 statistic (Deeks 2009),
a quantity which approximately describes the proportion of vari-
ation in point estimates that is due to heterogeneity rather than
sampling error. We followed the guide on interpretation of the I2
statistic as suggested by the Cochrane Handbook:
• 0% to 40%, might not be important;
• 30% to 60%, may represent moderate heterogeneity;
• 50% to 90%, may represent substantial heterogeneity;
• 75% to 100%, considerable heterogeneity.
In addition, a Chi2 test of homogeneity was employed to deter-
mine the strength of evidence that heterogeneity was genuine. If
significant heterogeneity (P < 0.1) was present, trials would be in-
vestigated for possible explanations. Sensitivity analyses excluding
outlying results would be performed.
Assessment of reporting biases
Funnel plots (estimated differences in treatment effects against
their standard errors) would be drawn if sufficient studies (more
than 10) were found. Asymmetry could be due to publication bias
but could also be due to a relationship between trial size and effect
size. In the event that a relationship was found, clinical diversity
of the studies would be examined (Sterne 2009).
Data synthesis
Where the interventions were the same, or similar enough, we
would synthesized results in a meta-analysis if there was no im-
portant clinical heterogeneity. Meta-analyses would be performed
using a fixed-effect model (for example the generic inverse vari-
ance method for survival data outcomes and the Mantel-Haenszel
method for dichotomous data outcomes).
Subgroup analysis and investigation of heterogeneity
If data permitted, we would conduct subgroup analyses for:
1. different age groups (younger than 12 years, 12 to 18 years,
older than 18 years);
2. different types of underlying hematological malignancies
(acute leukemia, chronic leukemia, lymphoma, etc);
3. different phases of therapy (before chemotherapy, during
intensive chemotherapy, during maintenance chemotherapy,
post-therapy);
4. whether patients had or had not received hematopoietic
stem cell transplant;
5. whether previous similar vaccines have been given (yes, no).
Sensitivity analysis
Sensitivity analyses would be conducted to assess the impact of
study quality. These would include:
1. all studies;
2. only those studies with adequate allocation concealment.
Sensitivity analyses would also be conducted to assess the impact
of heterogeneity, by excluding those studies with outlying results.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of ongoing
studies.
Results of the search
The search of CENTRAL (The Cochrane Library), MEDLINE,
EMBASE and CINAHL yielded 194, 125, 326 and 4 results re-
spectively. The search of other sources yielded one additional study.
There were a total of 565 articles for screening after duplicates
were removed; 557 studies were excluded based on information in
the title or abstract. Full texts of the remaining eight studies were
further assessed for eligibility and were included (Table 1). There
was one additional RCT that had just completed recruitment and
analysis results are pending (NCT01016548). This was therefore
excluded from further analyses in the current review.
Included studies
Altogether, eight RCTs met the inclusion criteria (Musto 1997;
Parkkali 1997; Redman 1997;Hata 2002; Hsieh 2002; Ljungman
2005; Safdar 2006; Esposito 2010). Details of the included studies
are given in the ’Characteristics of included studies’ table and are
summarized below.
The eight trials included a total of 593 people with hematological
malignancies, with 305 in the intervention groups and 288 in the
control groups. Two of the trials evaluated the efficacy of heat-
inactivated varicella zoster virus (VZV) vaccines (Redman 1997;
Hata 2002). Five trials evaluated influenza vaccines (Musto 1997;
Hsieh 2002; Ljungman 2005; Safdar 2006; Esposito 2010). In
one of these trials, the patients were randomized to three different
intervention groups (with nine, six and six participants) of three
different doses of the recombinant vaccine and one control group
(with six participants) of the standard vaccine. One trial evaluated
inactivated poliovirus (IPV) vaccine (Parkkali 1997). There were
no randomized controlled trials on other viral vaccines in patients
with hematological malignancies.
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Trials on heat-inactivated varicella zoster vaccine
Both of the VZV vaccine trials compared inactivated VZV vac-
cine with conventional care alone or placebo (Redman 1997;Hata
2002). The first trial included patients who had lymphoma and
were scheduled for autologous stem cell transplantation (Hata
2002) while the second trial included patients with leukemia or
lymphoma who were to receive autologous or allogeneic stem cell
transplantation (Redman 1997). In the first trial, the patients in
the intervention group received four doses of VZV vaccine, with
the first dose given within the 30 days before stem cell transplan-
tation (SCT), and subsequent doses given at 30, 60, and 90 days
after SCT (Hata 2002). Patients in the control group received
conventional care without VZV vaccine.
The second trial actually included two protocols in two different
study periods (Redman 1997). In the first study protocol in 1993,
the patients in the intervention group received a single dose of
VZVvaccine at onemonth post-SCT. In the second study protocol
in 1994 to 1995, the patients in the intervention group were given
three doses of VZV vaccine at one, two and three months post-
SCT.
The first trial (Hata 2002) included patients 18 to 60 years old
while the second trial (Redman 1997) included patients aged 18 to
49 years. The first trial recruited 119 patients, with 59 randomly
allocated to the intervention group and 60 allocated to the con-
trol group (Hata 2002). The baseline characteristics of patients
in both groups were not entirely comparable because there were
more patients with Hodgkin’s disease in the control group and
more post-first remission non-Hodgkin lymphoma patients in the
intervention group. In the second trial, 28 patients were recruited
to the first protocol, with 14 allocated to the intervention group
and 14 to the control group (Redman 1997). The second proto-
col included 47 participants, with 24 in the intervention group
and 23 in the control group. The baseline characteristics of the
patients in the two groups were not entirely comparable because
there were more patients with chronic myeloid leukemia in the
control group in the second protocol.
All included patients in both trials had to be seropositive for VZV
before SCT but there was no history of zoster or exposure to VZV
within one month after SCT. In both trials, the baseline VZV titre
of the participants were between 1:256 and 1:16384 and did not
differ between the intervention and control groups. Both trials
reported outcomes of incidence of herpes zoster, mortality due to
varicella or herpes zoster, all-cause mortality, frequency of patients
with a 4-fold rise in antibody titres and in vitro mean lymphocyte
stimulation index. Both trials also evaluated cytokine production
but the results were presented in different ways. The first trial
evaluated the percentage of CD4+ T-cells that produced TNF-
alpha or Interferon-gamma (Hata 2002) while the second trial re-
ported the concentrations of interferon-gamma and interleukin-
10 (Redman 1997). The zoster severity score was reported in the
second trial (Redman 1997) but there was no data on compli-
cations and hospitalization due to zoster infection in either trial.
Frequencies of systemic and local adverse effects were reported in
both trials.
Trials on influenza vaccines
Two of the influenza vaccine trials compared the standard triva-
lent inactivated influenza vaccine with no vaccine (Musto 1997;
Esposito 2010). One trial compared the standard split virus triva-
lent inactivated influenza vaccine with three different doses of
a recombinant baculovirus-expressed trivalent influenza vaccine
(Safdar 2006). Another trial compared two doses of trivalent in-
activated influenza vaccine with a single dose (Ljungman 2005).
The remaining trial compared two different schedules involving
two doses of trivalent inactivated influenza vaccine (Hsieh 2002).
The trial by Esposito only included children who had acute lym-
phoblastic leukemia or lymphoma (Esposito 2010). The trial by
Musto only included adults who had multiple myeloma (Musto
1997). The trial by Safdar only included adult patients with non-
Hodgkin’s lymphoma (Safdar 2006). The trial by Ljungman in-
cluded patients with leukemia, lymphoma, multiple myeloma or
Waldenstrom’smacroglobulinemia (Ljungman 2005). The trial by
Hsieh only included children with acute lymphoblastic leukemia
(Hsieh 2002). Patients in these trials had received chemotherapy
with or without antibody therapy (rituximab, alemtuzumab or
bortezomib).
The trial by Esposito randomly allocated 182 patients to receive
one to two doses (depending on age) of influenza vaccine or no
vaccine after stratifying into two groups according to the length
of time after completion of chemotherapy (< 6 months or 6 to 24
months) (Esposito 2010). The trial by Musto randomly allocated
50 patients who were undergoing conventional chemotherapy in
November 1995 to either receive or not receive influenza vaccine
(Musto 1997). The trial by Safdar randomly allocated 27 patients
to three intervention groups of recombination vaccine at different
doses (15 µg hemagglutinin protein/0.5 ml, 45 µg/0.5 ml and
135 µg/0.5 ml) and one control group of standard vaccine at 15
µg hemagglutinin protein/0.5 ml (Safdar 2006). The timing of
vaccination in relation to diagnosis and completion of chemother-
apy was variable but was at least three months after chemother-
apy. The trial by Ljungman randomly allocated 70 patients to a 2-
dose regime given four weeks apart or a 1-dose regime (Ljungman
2005). Again the timing of vaccination in relation to diagnosis
and completion of chemotherapy was variable but was during or
within six months of completion of chemotherapy. The trial by
Hsieh randomly allocated 25 patients to two different schedules
of two doses of vaccine (Hsieh 2002). In protocol one (interven-
tion group), the first dose of vaccine was given with re-induction
chemotherapy and a second dose was given four weeks later. In
protocol two (control group), the first dose of vaccine was given
four weeks before re-induction chemotherapy and a second dose
was given with re-induction chemotherapy four weeks later.
Previous vaccination history of the participancts and baseline an-
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tibody levels were not mentioned in any of the five trials. The
baseline characteristics of the participants were not presented in
three trials (Musto 1997; Hsieh 2002; Safdar 2006). In one of the
remaining trials, the baseline characteristics of the participants in
the intervention and the control groups were not entirely compa-
rable because patients in the control group had a higher median
age (Ljungman 2005). The trials by Esposito and Musto both re-
ported the frequency of upper respiratory infections (Musto 1997;
Esposito 2010). The trial by Esposito also reported the frequency
of lower respiratory tract infections, at least one infection other
than influenza-like illness, at least one hospitalization, the num-
ber of upper and lower respiratory tract infections, the number of
days with fever, the number of antibiotic courses and the number
of days lost from school (Esposito 2010). The trial by Musto also
reported the frequency of upper respiratory illnesses, pneumonia,
mortality and hospitalization due to pneumonia, the duration of
febrile respiratory episodes and the number of non-programmed
visits to hospital (Musto 1997). Three trials evaluated the fre-
quency of patients with a 4-fold rise in antibody titres four weeks
after vaccination (Hsieh 2002; Ljungman 2005; Safdar 2006). The
trial by Ljungman also reported the frequency of patients with
protective antibodies (titre > 40) (Ljungman 2005) while the trial
by Hsieh reported the frequency of patients with seroconversion
(increase in titre from below 40 to no less than 40) (Hsieh 2002).
Frequency of adverse effects were mentioned in four trials (Musto
1997;Hsieh 2002; Safdar 2006; Esposito 2010), but in three trials
these frequencies were not separately reported for the intervention
and the control groups (Musto 1997; Hsieh 2002; Safdar 2006).
There were no data on incidence of or mortality from influenza
infection, all-causemortality, or complications and hospitalization
due to influenza infection in any of the trials.
Trial on inactivated poliovirus vaccine (IPV)
Therewas only one includedRCTon IPVvaccine (Parkkali 1997).
The trial compared two different dosing schedules of IPV vaccine
for patients, aged above 16 years, with hematological malignancies
and who had received matched sibling SCT. The authors aimed
to test whether earlier IPV vaccination after SCT induced similar
immunological responses compared to delayed vaccination post-
SCT. Patients in the intervention group in this trial received IPV
vaccine subcutaneously at 6, 8 and 14 months after SCT while
the control group received the vaccine at 18, 20 and 26 months
post-SCT. Forty-five participants were randomized, with 23 al-
located to the early vaccination arm and 22 to the late vaccina-
tion arm. There were no differences in the gender ratio or median
age between the two groups. However, there were more patients
with chronic myeloid leukemia in the late vaccination group and
more patients with chronic graft-versus-host disease in the early
vaccination group. The vaccination history of the participants was
not reported. The geometric mean titres of the participants be-
fore vaccination ranged from 180 to 1029 for the three poliovirus
serotypes and were significantly higher in the early vaccination
group compared to the late vaccination group. Outcomes reported
were geometric mean antibody titre and the frequency of patients
with a 4-fold rise in protective antibodies.
Risk of bias in included studies
Seven of the eight included trials had high risk of bias (Musto
1997; Parkkali 1997; Redman 1997; Hata 2002; Hsieh 2002;
Ljungman 2005; Esposito 2010) and one trial had moderate risk
of bias (Safdar 2006) by our pre-defined criteria.
Allocation
None of the trials reported on randomization sequence generation
or allocation concealment and hence whether the trials were at risk
of selection bias is unclear.
Blinding
Four trials blinded the treating physicians (Redman 1997; Hata
2002; Safdar 2006; Esposito 2010) but only one trial blinded the
patients as well (Safdar 2006). Blinding of outcome assessors was
unknown in five trials (Parkkali 1997; Redman 1997; Hata 2002;
Safdar 2006; Esposito 2010) and not used in the remaining three
trials (Musto 1997; Hsieh 2002; Ljungman 2005).
Incomplete outcome data
The trial by Hata (Hata 2002) reported nine drop-outs (15.3%)
in the intervention group, including two patients who withdrew
at 30 days for unexplained reasons. For the other seven patients,
the reasons for drop-out were probably unrelated to vaccination
(six did not undergo transplantation after randomization and one
withdrewbecause of disease progression). Therewere altogether 16
patients in the intervention group (27.1%) who did not complete
the intended four doses of vaccine. There were two patient with-
drawals (3.3%) in the control group, both because of no transplan-
tation after randomization. For individual outcomes, the amount
ofmissingdatawas variable andup to67.8% for twooutcomes (the
proportion of CD4+ T-cells that produced TNF-alpha and the
proportion of CD4+ T-cells that produced interferon-gamma). In
the trial by Redman (Redman 1997), there was no drop-out re-
ported but missing data occurred in up to 73.9% in the interven-
tion and the control groups in one of the outcomes (post-stimula-
tion interleukin-10 concentrations at 12 months). In the trial by
Hsieh (Hsieh 2002), no drop-out was reported but missing data
occurred in up to 72.7% in the control group in two of the out-
comes (seroconversion in influenza A/H1 antibody after one and
two doses of vaccine). In the trials by Musto (Musto 1997) and
Ljungman (Ljungman 2005), no drop-out was reported but re-
ported data were insufficient to assess the amount of missing data.
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In the trial by Esposito (Esposito 2010) and Safdar (Safdar 2006),
no drop-out was reported and data on outcomes were complete.
In the trial by Parkkali (Parkkali 1997), nine drop-outs (34.6%)
occurred in the treatment group, including two who died before
vaccination, one who had not received the vaccine and six losses to
follow up for unknown reasons. There were 12 drop-outs (41.4%)
in the control group, including six who died before vaccination,
one who relapsed and was not vaccinated, and five losses to follow
up with unknown reasons. Missing data occurred in up to 31.8%
in the control group for several outcomes (4-fold rise of antibody
titres to poliovirus types 1, 2 and 3; and geometric mean titre of
poliovirus antibody to poliovirus types 1, 2 and 3).
Other potential sources of bias
None of the included trialsmentioned the use of intention-to-treat
analysis. In addition, the intervention and the control groups were
not entirely comparable at baseline in four trials (Parkkali 1997;
Redman 1997; Hata 2002; Ljungman 2005). In three trials, the
comparability of the twogroups at baselinewas doubtful because of
inadequate information (Musto 1997; Hsieh 2002; Safdar 2006).
Effects of interventions
There were only trials for evaluation of varicella zoster vaccine,
influenza vaccine and poliomyelitis virus vaccine. There were no
included trials evaluating vaccines for hepatitis A, hepatitis B,
measles, mumps or rubella.
Trials on varicella zoster vaccine (VZV)
VZV vaccine versus no vaccine
Primary outcome
Incidence of herpes zoster
VZV vaccine seemed to be associated with a reduced risk of her-
pes zoster (RR 0.54, 95% CI 0.30 to 1.00, P = 0.05) when the
results of the two included trials (Redman 1997; Hata 2002) were
combined, but this was not statistically significant (Analysis 1.1;
Figure 1). There appeared to be heterogeneity between the two
included trials, with one trial showing a dramatic difference in the
incidence of herpes zoster between the intervention and the con-
trol groups (Hata 2002) and the other trial showing a remarkably
similar incidence in the two groups (Redman 1997). This might
be explained by the marked differences between the participants
(different age groups, underlying diseases, types of transplants re-
ceived), which is more heterogeneous in the trial showing the neg-
ative result (Redman 1997). There were also differences between
the trials with respect to co-interventions, acyclovir not routinely
given in one trial (Hata 2002) but given during a herpes simplex
virus (HSV) outbreak in another trial (Redman 1997), and the
schedules of the vaccines given, which may influence the efficacy
of the vaccines.
Figure 1. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.1 Incidence of herpes zoster.
Secondary outcomes
Mortality due to infection
There was no reported mortality due to varicella or herpes zoster
in any of the treatment groups in the two included trials (Redman
1997; Hata 2002) (Analysis 1.2).
All-cause mortality
There was no significant differences in all-cause mortality between
the intervention and the control groups (Analysis 1.3; Figure
2) when the results of the two included trials were combined (
Redman 1997; Hata 2002).
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Figure 2. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.3 All cause mortality.
In vitro immune response
Four-fold rise in VZV antibody titre
There was no significant difference between the intervention and
the control groups in the frequency of participants who had at
least a 4-fold rise in VZV antibody titre when the results of the
two trials were combined (Redman 1997; Hata 2002) (Analysis
1.4; Figure 3).
Figure 3. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.4 4-fold rise in VZV antibody
titre.
Lymphocyte stimulation index
When results of the two trials were combined (Redman 1997;
Hata 2002), the lymphocyte stimulation indices were significantly
higher in the intervention group compared to the control group
when measured at three months (MD 7.63, 95% CI 6.60 to 8.66,
P < 0.00001), four months (MD 10.92, 95% CI 2.13 to 19.71,
P = 0.01) or 12 months (MD 29.45, 95% CI 8.51 to 50.39, P
= 0.006) but not at one month or five to six months after the
vaccination (Analysis 1.5; Figure 4).
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Figure 4. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.5 Lymphocyte stimulation
index.
Percentages of CD4+ T-cells producing TNF-alpha or
interferon-gamma
One trial (Hata 2002) reported these outcomes and showed higher
percentages of CD4+ T-cells producing TNF-alpha (MD 31.00,
95%CI 24.75 to 37.25, P < 0.00001) (Analysis 1.6) or interferon-
gamma (MD 22.00, 95% CI 16.57 to 27.43, P < 0.00001) in the
intervention group compared to the control group (Analysis 1.7).
Post-stimulation interferon-gamma or interleukin-10
concentrations
One trial (Redman 1997) evaluated these cytokine levels and
found that the post-stimulation interferon-gamma concentration
in the intervention group was significantly higher at one month
(MD 8.00, 95% CI 2.39 to 13.61, P = 0.005) and four months
(MD74.00, 95%CI 22.75 to 125.25, P = 0.005), but significantly
lower at two months (MD -107.00, 95% CI -206.58 to -7.42,
P = 0.04) and not significantly different from the control group
at three months, five months and 12 months (Analysis 1.8). The
post-stimulation interleukin-10 concentration in the intervention
group was significantly lower at one month (MD -33.00, 95% CI
-56.78 to -9.22, P = 0.007) and four months (MD -56.00, 95%
CI -97.22 to -14.78, P = 0.008) but not at two months, three
months, five months and 12 months (Analysis 1.9).
Frequency of adverse effects
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Frequency of systemic adverse effects
When the results of the two trials were combined (Redman 1997;
Hata 2002) there seemed to be more systemic adverse effects in
the intervention group, which did not reach statistical significance
(RR 5.94, 95% CI 0.73 to 48.55, P = 0.1) (Analysis 1.10; Figure
5).
Figure 5. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.10 Frequency of systemic
adverse effects.
Frequency of local adverse effects
After combining the results of the two trials (Redman 1997;
Hata 2002), significantly more patients in the intervention group
experienced local adverse effects at the injection site (RR 20.94,
95% CI 2.88 to 152.36, P = 0.003) (Analysis 1.11; Figure 6).
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Figure 6. Forest plot of comparison: 1 VZV vaccine vs. no vaccine, outcome: 1.11 Frequency of local
adverse effects.
There were no data on other pre-defined secondary outcomes (in-
cidence of complications or severe infections or rate of hospital-
ization).
Additional outcomes
Severity score of herpes zoster
One trial (Redman 1997) reported a significantly higher herpes
zoster severity score in patients who developed herpes zoster in
the control group compared to the intervention group. The mean
difference in the score was 2.6 points out of a maximum of 20
points (MD 2.60, 95% CI 0.94 to 4.26, P = 0.002) (Analysis
1.12). The other included trial just commented that the severity
of the herpes zoster did not differ between the intervention and
control groups and actual data were not available (Hata 2002).
Trials on influenza vaccines
Influenza vaccine versus no vaccine
Primary outcome
Incidence of influenza
There was no data on this pre-defined primary outcome from the
included trials (Musto 1997; Esposito 2010).
Secondary outcomes
Mortality due to infection (pneumonia)
The mortality due to pneumonia was reported in one included
trial (Musto 1997), which was not significantly different between
the intervention and control groups (Analysis 2.1).
Incidence of complications
Frequency of at least one lower respiratory infection
When the results of the two included trials were combined (Musto
1997; Esposito 2010), the risk of at least one lower respiratory
infection was significantly lower in the intervention group (RR
0.39, 95% CI 0.19 to 0.78, P = 0.008) (Analysis 2.2; Figure 7).
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Figure 7. Forest plot of comparison: 2 Influenza vaccine vs. no vaccine, outcome: 2.2 Incidence of
complications.
Frequency of at least one infection other than influenza-like
illness
One trial (Esposito 2010) reported the number of patients with at
least one infection other than influenza-like illness and found no
significant difference between the intervention and control groups
(Analysis 2.2).
Rate of hospitalization
When the results of the two included trials (Musto 1997; Esposito
2010) were combined, the hospitalization rate was significantly
lower in the intervention group (RR 0.17, 95% CI 0.09 to 0.31,
P < 0.00001) (Analysis 2.3; Figure 8). One included trial (Musto
1997) also reported that the number of non-programmed visits
to hospital was significantly lower in the intervention group com-
pared to the control group (0.5 versus 2.3, P < 0.001). However,
the results could not be tabulated or verified.
Figure 8. Forest plot of comparison: 2 Influenza vaccine vs. no vaccine, outcome: 2.3 Rate of hospitalization.
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Frequency of adverse effects
Frequency of at least one adverse effects
When the results of the two included trials were combined (Musto
1997; Esposito 2010), the frequency of at least one adverse effects
was significantly higher in the intervention group (RR 35, 95%
CI 4.9 to 249.8, P = 0.0004) (Analysis 2.4; Figure 9).
Figure 9. Forest plot of comparison: 2 Influenza vaccine vs. no vaccine, outcome: 2.4 Frequency of at least
one adverse effects.
Frequency of systemic adverse effects
One of the included trials (Esposito 2010) reported the frequen-
cies of different systemic adverse effects and showed a significantly
higher frequency of irritability in the intervention group (RR 19,
95%CI 1.12 to 321.07, P = 0.04) (Analysis 2.5). The frequency of
other systemic adverse effects, including fever, decreased appetite,
rhinitis, cough and vomiting, were not significantly different be-
tween the intervention and control groups (Analysis 2.5).
Frequency of local adverse effects
When the results of the two included trials were combined (Musto
1997; Esposito 2010), the frequency of at least one local adverse
effect was significantly higher in the intervention group (RR 22,
95% CI 3.05 to 158.51, P = 0.002) (Analysis 2.6; Figure 10).
One trial (Esposito 2010) reported the frequency of different local
adverse effects (redness, swelling or induration), which were not
significantly different between the intervention and control groups
(Analysis 2.6).
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Figure 10. Forest plot of comparison: 2 Influenza vaccine vs. no vaccine, outcome: 2.6 Frequency of local
adverse effects.
There were no data on other pre-defined secondary outcomes (all-
cause mortality, incidence of severe infections or in vitro immune
response).
Additional outcomes
Frequency of at least one upper respiratory infections
When the results of the two included trials were combined (Musto
1997; Esposito 2010), participants in the intervention group had
a significantly lower risk of experiencing at least one upper respi-
ratory infection (RR 0.56, 95% CI 0.44 to 0.72, P < 0.00001)
(Analysis 2.7).
Number of upper respiratory tract infections
One included trial (Esposito 2010) reported that the intervention
group had significantly fewer upper respiratory tract infections
(MD -1.23, 95% CI -1.52 to -0.94, P < 0.00001) (Analysis 2.8).
Number of lower respiratory tract infections
One included trial (Esposito 2010) reported that the intervention
group had significantly fewer lower respiratory tract infections
(MD -0.3, 95% CI -0.44 to -0.16, P < 0.00001) (Analysis 2.9).
Number of infections other than influenza-like illness
One included trial (Esposito 2010) reported the outcome of num-
ber of infections other than influenza-like illness, which was not
significantly different between the intervention and control groups
(Analysis 2.10).
Number of days with fever
One included trial (Esposito 2010) reported that the intervention
group had significantly fewer days with fever (MD -1.7, 95% CI
-2.25 to -1.15, P < 0.00001) (Analysis 2.11).
Number of antibiotics courses
One included trial (Esposito 2010) reported that the intervention
group received significantly fewer antibiotics courses (MD -1.85,
95% CI -2.3 to -1.4, P < 0.00001) (Analysis 2.12).
Number of days lost from school
One included trial (Esposito 2010) reported that the intervention
group had significantly lower number of days lost from school
(MD -4.94, 95% CI -5.65 to -4.23, P < 0.00001) (Analysis 2.13).
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Duration of febrile respiratory episodes
One included trial (Musto 1997) reported that the mean dura-
tion of febrile respiratory episodes was significantly lower in the
intervention group compared to the control group (5 days versus
12 days, P < 0.001). However, since no standard deviation, CI or
actual P value was provided the results could not be tabulated or
verified.
Influenza vaccine, two doses versus single dose
Primary outcome
Incidence of influenza
There were no data on this pre-defined primary outcome from the
included trial (Ljungman 2005).
Secondary outcomes
In vitro immune response
Four-fold rise in antibody titre
In the trial comparing two doses to one dose of influenza vaccine
(Ljungman 2005), there was no significant difference between the
two groups in the proportion of patients who attained a 4-fold rise
in antibody titres to any of the three components (A/H3, A/H1,
B) of the vaccine (Analysis 3.1).
Antibody titre above 1:40
Consistent with the above results, there was no significant differ-
ence between the intervention and the control groups in the pro-
portion of patients who attained antibody titres above 1:40 to any
of the three components (A/H3, A/H1, B) of the vaccine (Analysis
3.2).
There were no data on other pre-defined secondary outcomes
(mortality due to infection, all-cause mortality, incidence of com-
plications or severe infections, rate of hospitalization or frequency
of adverse effects).
Recombinant influenza vaccine versus standard influenza
vaccine
Primary outcome
Incidence of influenza
There were no data on this pre-defined primary outcome from the
included trial (Safdar 2006).
Secondary outcomes
In vitro immune response
Four-fold rise in antibody titre
In the trial comparing recombinant influenza vaccine to standard
inactivated influenza vaccine (Safdar 2006), when the dose of 15
µg recombinant vaccine was compared to control vaccine, there
was no significant difference between the two groups in the pro-
portion of patients who attained 4-fold rise in antibody titres
to any of the three components (A/H3, A/H1, B) of the vac-
cine, whether this was measured by hemoagglutination inhibition
(Analysis 4.1), neutralizing antibody (Analysis 4.2) or both results
combined (Analysis 4.3).
When the dose of 45 µg recombinant vaccine was compared to
control vaccine, there was generally no significant difference be-
tween the intervention and the control groups in the proportion
of patients who attained a 4-fold rise in antibody titres to any of
the three components (A/H3, A/H1, B) of the vaccine, whether
this wasmeasured by hemoagglutination inhibition (Analysis 5.1),
neutralizing antibody (Analysis 5.2) or both results combined
(Analysis 5.3). The only exception was that there was a marginally
significantly higher frequency of patients in the intervention group
who attained a 4-fold rise in neutralizing antibody titre to the
A/H3 component (RR 4.33, 95% CI 1.03 to 18.17, P = 0.04)
(Analysis 5.2).
When the dose of 135 µg recombinant vaccine was compared to
control vaccine, there was no significant difference between the
intervention and the control groups in the proportion of patients
who attained a 4-fold rise in antibody titres to any of the three
components (A/H3, A/H1, B) of the vaccine, whether this was
measured by hemoagglutination inhibition (Analysis 6.1), neutral-
izing antibody (Analysis 6.2) or both results combined (Analysis
6.3).
There were no data on other pre-defined secondary outcomes
(mortality due to infection, all-cause mortality, incidence of com-
plications or severe infections, rate of hospitalization or frequency
of adverse effects).
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Comparison of different influenza vaccine schedules: first
dose versus second dose given with re-induction
Primary outcome
Incidence of influenza
There were no data on this pre-defined primary outcome from the
included trial (Hsieh 2002).
Secondary outcomes
In vitro immune response
Four-fold rise in antibody titre
In the trial comparing different influenza schedules of two doses
(Hsieh 2002), there was no significant difference between the two
groups in the proportion of patients who attained a 4-fold rise in
antibody titres to any of the three components (A/H3, A/H1, B)
of the vaccine after the first dose (Analysis 7.1) or the second dose
(Analysis 7.2).
Seroconversion
Consistent with the above results, there was also no significant dif-
ference between the two groups in the proportion of patients who
achieved seroconversion (increase of antibody titre from below 40
to no less than 40) to any of the three components (A/H3, A/H1,
B) of the vaccine after the first dose (Analysis 7.3) or the second
dose (Analysis 7.4).
There were no data on other pre-defined secondary outcomes
(mortality due to infection, all-cause mortality, incidence of com-
plications or severe infections, rate of hospitalization or frequency
of adverse effects).
Trial on inactivated poliovirus vaccine
Early schedule versus late schedule
Primary outcome
Incidence of poliomyelitis
There were no data on this pre-defined primary outcome from the
included trial (Parkkali 1997).
Secondary outcomes
In vitro immune response
Four-fold rise in antibody titre
In the trial comparing early (starting six months after stem cell
transplant) and late (starting 18 months after stem cell transplant)
schedules of inactivated poliovirus vaccine in three doses (Parkkali
1997), there was generally no significant difference between the
two groups in the proportion of patients who attained a 4-fold
rise in antibody titres to any of the three poliovirus serotypes after
the first dose (Analysis 8.1), the second dose (Analysis 8.2) or the
third dose of the vaccine (Analysis 8.3). The only exception was
that there were significantly fewer patients in the early schedule
group who attained a 4-fold rise in antibody titre to polio type 2
(RR 0.34, 95% CI 0.15 to 0.8, P = 0.01) and type 3 (RR 0.57,
95% CI 0.34 to 0.96, P = 0.03) after the first dose (Analysis 8.1).
Geometric mean titre of protective antibody
The authors reported the geometric mean titres of protective an-
tibody to poliovirus types 1, 2 and 3 before and after each dose of
vaccination. There was no significant difference between the two
groups in any of these antibody titres. Since no standard deviation,
CI or actual P value for these geometric means were provided, the
results could not be tabulated or verified.
There were no data on other pre-defined secondary outcomes
(mortality due to infection, all-cause mortality, incidence of com-
plications or severe infections, rate of hospitalization or frequency
of adverse effects).
Assessment of reporting biases
Since there were at most only two trials reporting on the same
comparisons, funnel plots were not constructed.
Subgroup analysis and investigation of heterogeneity
Since no individual or stratified data on pre-defined subgroups
were available, subgroup analysis was not performed. Since there
were at most only two trials reporting on the same comparisons,
formal investigation of heterogeneity was impossible.
Sensitivity analyses
Sensitivity analyses were not performed to assess the impact of
including studies of different quality since there were only two
trials at most for all comparisons. Similarly, sensitivity analyses
were not performed to assess the impact of heterogeneity.
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D I S C U S S I O N
Summary of main results
In the current review on the use of viral vaccines for patients
with hematological malignancies, evidence from randomized con-
trolled trials is limited and available for only three viral diseases,
namely varicella zoster virus (VZV), influenza virus andpoliovirus.
There are no included trials evaluating vaccines for hepatitis A,
hepatitis B, measles, mumps or rubella. Only the two trials on
VZV vaccine reported our pre-defined primary outcome (Redman
1997; Hata 2002). All trials reported some of the pre-defined
secondary outcomes. Two trials on VZV vaccine (Redman 1997;
Hata 2002) and one trial on influenza vaccine (Esposito 2010) also
reported some additional outcomes not pre-defined in the current
review.
There are only two small RCTs evaluating heat-inactivated VZV
vaccine compared to no vaccine for patients with leukemia or lym-
phoma (Redman 1997; Hata 2002). The combined results of the
two trials suggest that VZV vaccine might be effective in prevent-
ing herpes zoster or reducing the severity of herpes zoster. How-
ever, the immunogenicity of the vaccine in these patients is in-
conclusive. The VZV vaccine is associated with significantly more
local adverse effects. Systemic adverse effects such as headache,
arthralgia and myalgia also appear to be more common in vaccine
recipients, although this was not statistically significant.
Although there are five RCTs evaluating influenza vaccines for pa-
tients with hematological malignancies, the objectives of the trials
and the target patient populations are very heterogeneous. The re-
sults from two RCTs (Musto 1997; Esposito 2010) could be com-
bined. These two trials compared influenza vaccine with no vac-
cine in entirely different patient groups, one in adults with multi-
ple myeloma undergoing chemotherapy and the other in children
who had finished chemotherapy treatment for leukemia or lym-
phoma. The pooled results suggest that inactivated influenza vac-
cine might be effective in preventing upper and lower respiratory
infections and reducing hospitalization. One trial (Esposito 2010)
also suggested that the vaccinemay reduce the number of days with
fever, the number of antibiotics courses and the number of days
lost from school. However, it is uncertain whether the reported
respiratory illnesses and hospitalizations were related to influenza
or not; and there is no conclusive evidence that influenza vaccine
reduces influenza-related mortality in patients with hematologi-
cal malignancies. The trial comparing two doses with one dose
of the influenza vaccine in patients with various hematological
malignancies within six months of completion of chemotherapy
shows no significant differences in antibody response (Ljungman
2005). The antibody response after different doses of recombinant
influenza vaccine was similar to the standard trivalent inactivated
influenza vaccine in non-Hodgkin’s lymphoma patients who had
finished chemotherapy for at least three months (Safdar 2006).
The antibody response was also similar whether or not influenza
vaccine was given with re-induction chemotherapy in children
with acute lymphoblastic leukemia (Hsieh 2002). Systemic and
local adverse effects are not uncommon in influenza vaccine re-
cipients, although it is uncertain from the trial reports whether
the frequency of adverse effects is different in different types of
vaccines or different vaccination schedules.
For inactivated poliovirus vaccine in adult stem cell transplant
recipients, the antibody response was generally not significantly
different whether the 3-dose vaccination series was started at six
months or 18 months post-transplant, although the frequency of
patients achieving 4-fold rise in antibody titre tended to be lower
with the early schedule (Parkkali 1997). There was no information
on adverse effects in the included trial.
The patient population and clinical setting in the included trials
were highly variable and therefore a generalizable conclusion is
difficult to make. In adults who have received hematopoietic stem
cell transplantation for leukemia or lymphoma, VZV vaccination
might be effective in preventingherpes zoster (Redman 1997;Hata
2002). Immunogenicity of inactivated poliovirus vaccine is vari-
able and there was no significant difference whether it was given
early or late post-SCT (Parkkali 1997). In adults with hematolog-
ical malignancies undergoing or in the period shortly after chemo-
therapy, influenza vaccine might reduce upper respiratory infec-
tions and hospitalizations (Musto 1997). However, there was no
sigificant difference between one and two doses (Ljungman 2005),
or between recombinant and standard vaccine (Safdar 2006). In
children with acute lymphoblastic leukemia or lymphoma, in-
fluenza vaccine givenwithin two years of completon of chemother-
apy might reduce upper and lower respiratory infections (Esposito
2010). There was no significant difference whether influenza vac-
cine was given with re-induction or not during maintenance che-
motherapy (Hsieh 2002).
Overall completeness and applicability of
evidence
High level evidence on the efficacy and safety of viral vaccines
in patients with hematological malignancies is scarce, incomplete
and limited to varicella zoster, influenza and poliomyelitis viruses
only. There are no included trials evaluating vaccines for hepatitis
A, hepatitis B, measles, mumps or rubella. Only the two trials on
VZV vaccine reported our pre-defined primary outcome (Redman
1997; Hata 2002). All trials reported some of the pre-defined
secondary outcomes. Two trials on VZV vaccine (Redman 1997;
Hata 2002) and one trial on influenza vaccine (Esposito 2010) also
reported some additional outcomes not pre-defined in the current
review. As the type of underlying malignancies and treatments are
restricted in many of these trials, the results of these trials cannot
be generalized to all patients with hematological malignancies.
VZV vaccine, when given before and after stem cell transplant in
adults with lymphoma or leukemia, might be efficacious in re-
ducing the incidence and severity of herpes zoster, which paral-
lels development of certain cell-mediated immunity (Hata 2002;
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Redman 1997). Whether VZV vaccine has similar efficacy in pa-
tients with other hematological malignancies or patients treated
with chemotherapy is uncertain.
Influenza vaccine might be effective in reducing the incidence
of upper and lower respiratory infections and hospitalization in
adults with multiple myeloma undergoing chemotherapy (Musto
1997) or childrenwith leukemia and lymphomawho finished che-
motherapy in the preceding two years (Esposito 2010). However,
it was uncertain what proportions of these infections or hospi-
talizations were caused by influenza. There appears to be no sig-
nificant difference between one and two doses (Ljungman 2005),
recombinant or standard inactivated vaccines (in adults with non-
Hodgkin’s lymphoma) (Safdar 2006) or scheduling the dose with
or without re-induction chemotherapy (in children with acute
lymphoblastic leukemia) (Hsieh 2002). However, these negative
results might be attributable to inadequate statistical power since
only small samples have been studied. In addition, the results can-
not be generalized to patientswithmalignancy types different from
patients recruited in these trials.
The only RCT on inactivated poliovirus vaccine compared differ-
ent starting times of the vaccination series after stem cell trans-
plantation, which demonstrates variable seroresponse to the vac-
cine that does not differ significantly whether the vaccination was
started at six or 18 months post-transplant (Parkkali 1997). Again
the sample size was limited and the conclusion may be falsely neg-
ative. The results are not applicable to patients other than trans-
plant recipients.
Adverse effects to these viral vaccines are not uncommon, espe-
cially local adverse effects, which occur in up to 60% of patients
who have received influenza vaccine (Musto 1997). However, no
serious adverse effects are reported in the included RCTs. Since
the number of patients recruited in each of these RCTs was small,
rare serious adverse events might not have been detected.
Quality of the evidence
Most of the RCTs included in the current review are considered
to have a high risk of bias and hence the quality of the evidence
is low. Most of the trials also focused on laboratory outcomes of
immunological response to vaccines instead of clinically relevant
outcomes in terms ofmorbidity ormortality prevented. As a result,
whether the surrogate outcomes translate into relevant clinical
benefits remains uncertain. All includedRCTs recruited only small
numbers of patients and only one trial (Hata 2002) pre-calculated
the sample size; they therefore lack statistical power in detecting
differences between the intervention groups and are susceptible to
false negative conclusions.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
VZV vaccine might be efficacious in reducing the incidence and
severity of herpes zoster when given before and after stem cell
transplant in adults with lymphoma or leukemia. Influenza vac-
cine might be effective in reducing the incidence of upper and
lower respiratory infections and hospitalization due to pneumo-
nia in adults with multiple myeloma undergoing chemotherapy
and children with leukemia and lymphoma who finished chemo-
therapy in the preceding two years. However, the quality of ev-
idence supporting these findings is low. Adverse effects to these
viral vaccines, both systemic and local, occur frequently although
serious adverse effects appear uncommon and most adverse effects
are tolerable. There is no RCT supporting the use of other viral
vaccines in patients with hematological malignancies. Clinicians
who wish to administer viral vaccines to these patients should bal-
ance the potential benefits against the potential risks and discuss
them with patients adequately so that they can make individual
informed choices.
Implications for research
The existing evidence on the efficacy and safety of viral vaccines for
patients with hematological malignancies is inadequate, incom-
plete and of low quality. Further randomized controlled trials are
needed to evaluate more of the available viral vaccines. These trials
should encompass patients of different age groups and a variety of
hematological malignancies treated with different modalities (che-
motherapy, immunotherapy, targeted therapy, autologous or allo-
geneic stem cell transplant), although individual trials might be
restricted to specific patient population to enhance homogeneity
among trial participants. Ideally, the trials should compare active
vaccines against placebo to determine the clinical efficacy of the
particular vaccine in these patient groups. Trials comparing dif-
ferent forms of vaccines in different doses, dosing schedules and
timings are also invaluable to inform clinicians on the optimal use
of available vaccines. The outcomes employed should be patient-
oriented and important, such as all-cause mortality, disease spe-
cific mortality, incidence of severe complications and hospitaliza-
tions, and incidence of the specific infection and severity scores, in
addition to the usual immunological laboratory parameters. The
sample size should be pre-calculated to ensure adequate statistical
power to detect important differences in the primary outcome.
The conduct of the trials should adhere to the current standards, of
which important components include concealed randomization
sequence generation; adequate blinding of participants, healthcare
teams, outcome reporters and analysts; intention-to-treat analy-
ses; and adequate reports of all outcomes and drop-outs. Cost-
effectiveness analyses are also needed before appropriate recom-
mendation can be made on the use of viral vaccines in patients
with hematological malignancies.
20Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A C K N OW L E D G E M E N T S
We thank the Library of theUniversity ofHongKong for retrieving
full texts of references.
R E F E R E N C E S
References to studies included in this review
Esposito 2010 {published data only}
Esposito S, Cecinati V, Scicchitano B, Delvecchio
GC, Santoro N, Amato D, et al.Impact of influenza-
like illness and effectiveness of influenza vaccination in
oncohematological children who have completed cancer
therapy. Vaccine 2010;28:1558–65.
Hata 2002 {published data only}
Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume
K, et al.Use of an inactivated varicella vaccine in recipients
of hematopoietic-cell transplants. New England Journal of
Medicine 2002;347:26–34.
Hsieh 2002 {published data only}
Hsieh Y, Lu M, Kao C, Chiang B, Lin D, Lin K, et
al.Response to influenza vaccine in children with leukemia
undergoing chemotherapy. Journal of the Formosan Medical
Association 2002;101(10):700–4.
Ljungman 2005 {published data only}
Ljungman P, Nahi H, Linde A. Vaccination of patients
with haematological malignancies with one or two doses of
influenza vaccine: a randomised study. British Journal of
Haematology 2005;130:96–8.
Musto 1997 {published data only}
Musto P, Carotenuto M. Vaccination against influenza in
multiple myeloma. British Journal of Haematology 1997;97
(2):505–6.
Parkkali 1997 {published data only}
Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P.
Randomized comparison of early and late vaccination with
inactivated poliovirus vaccine after allogeneic BMT. Bone
Marrow Transplantation 1997;20:663–8.
Redman 1997 {published data only}
Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown
BW, et al.Early reconstitution of immunity and decreased
severity of herpes zoster in bone marrow transplant
recipients immunized with inactivated varicella vaccine.
Journal of Infectious Diseases 1997;176(3):578–85.
Safdar 2006 {published data only}
Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B,
Wang M, et al.Dose-related safety and immunogenicity of
Baculovirus-expressed trivalent influenza vaccine: A double-
blind, controlled trial in adult patients with non-Hodgkin
B cell lymphoma. Journal of Infectious Diseases 2006;194:
1394–7.
References to ongoing studies
NCT01016548 {unpublished data only}
University Health Network, Toronto. Evaluation of
influenza H1N1 vaccine in adults with lymphoid
malignancies on chemotherapy. Clinicaltrials.gov.
Additional references
ACIP 2005
Advisory Committee on Immunization Practices (ACIP).
Prevention and control of influenza: recommendations of
the MMWR. Morbidity and Mortality Weekly Report 2005;
54:1–40.
Allison 1977
Allison JE, Glezen WP, Taber LH, Paredes A, Webster RG.
Reactogenicity and immunogenicity of bivalent influenza
A and monovalent influenza B virus vaccines in high-risk
children. Journal of Infectious Diseases 1977;136 Suppl:
672–6.
Arbeter 1990
Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer
R, Plotkin SA. Immunization of children with acute
lymphoblastic leukemia with live attenuated varicella
vaccine without complete suspension of chemotherapy.
Pediatrics 1990;85:338–44.
Austgulen 1985
Austgulen R. Immunization of children with malignant
diseases with the Oka-strain varicella vaccine. Postgraduate
Medical Journal 1985;61 Suppl 4:93–5.
Bancillon 1991
Bancillon A, Leblanc T, Baruchel A, Schaison G, Leverger
G, Mallarmey D, et al.Study of tolerance and effectiveness
of a varicella vaccine in leukemic children. Nouvelle Revue
Francaise d’Hematologie 1991;33:555–6.
Booth 2000
Booth LV, Coppin R, Dunleavey J, Smith H.
Implementation of influenza immunization policy in
general practice: 1997-1998. Communicable Disease and
Public Health 2000;3:39–42.
Borella 1971
Borella L, Webster RG. The immunosuppressive effects
of long-term combination chemotherapy in children with
acute leukemia in remission. Cancer Research 1971;31:
420–6.
Bosu 1975
Bosu SK, Ciudad H, Sinks LF, Ogra PI. Antibody response
to poliovirus immunization in childhood leukemia. Medical
and Pediatric Oncololgy 75;1:217–35.
21Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brown 1982
Brown AE, Steinherz PG, Miller DR, Armstrong D, Kellick
MG, Gross PA, et al.Immunization against influenza in
children with cancer: Results of a three-dose trial. Journal of
Infectious Diseases 1982;145:126.
Brunell 1982
Brunell PA, Shehab Z, Geiser C, Waugh JE. Administration
of live varicella vaccine to children wtih leukaemia. Lancet
1982;2:1069–73.
Brunell 1984
Brunell PA, Taylor-Wiedeman J, Shehab ZM, Geiser C,
Frierson LS, Cobb EK. Administration of varicella vaccine
to children with leukemia. Biken Journal 1984;27:83–8.
Brydak 1997
Brydak LB, Rokicka-Milewska R, Jackowska T, Rudnicka
H, Regnery H, Cox N. Kinetics of humoral response in
children with acute lymphoblastic leukemia immunized
with influenza vaccine in 1993 in Poland. Leukemia
Lymphoma 1997;26:163–9.
Brydak 1998
Brydak LB, Rokicka-Milewska R, Machala M, Jackowska
T, Sikorska-Fic B. Immunogenicity of subunit trivalent
influenza vaccine in children with acute lymphoblastic
leukemia. Pediatric Infectious Disease Journal 1998;17:
125–9.
Brydak 1999
Brydak LB, Calbecka M. Immunogenicity of influenza
vaccine in patients with hemato-oncological disorders.
Leukemia & Lymphoma 1999;32:369–74.
Brydak 2006
Brydak LB, Machala M, Centkowski P, Warzocha K,
Bilinski P. Humoral response to hemagglutinin components
of influenza vaccine in patients with non-Hodgkin
malignant lymphoma. Vaccine 2006;24:6620–3. [: PMID:
16870313]
Chisholm 2001
Chisholm JC, Devine T, Charlett A, Pinkerton CR,
Zambon M. Response to influenza immunization during
treatment for cancer. Archives of Disease in Childhood 2001;
84:496–500.
Christensen 1999
Christensen CL, Poulsen A, Bottiger B, Kirk M, Andersen
HK, Schmiegelow K. Complications in two children with
acute lymphatic leukemia caused by vaccination against
varicella zoster virus. Ugeskrift for Laeger 1999;161:794–6.
Deeks 2009
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing
data and undertaking meta-analyses. In: Higgins JPT,
Green S editor(s). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.0.2 (updated September 2009). The
Cochrane Collaboration, 2009.
DOH 1996
Department of Health. Immunization Against Infectious
Disease. London: HMSO, 1996.
Ecevit 1996
Ecevit Z, Buyukpamukcu M, Kanra G, Sevinir B, Ueda S.
Oka strain live varicella vaccine in children with cancer.
Pediatric Infectious Disease Journal 1996;15:169–70.
Elting 1995
Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey
GP. Epidemiology of influenza A virus infection in patients
with acute or chronic leukemia. Supportive Care in Cancer
1995;3:198–202.
Engelhard 1993
Engelhard D, Nagler A, Hardan I, Morag A, Aker M,
Baciu H, et al.Antibody response to a two-dose regimen
of influenza vaccine in allogeneic T cell-depleted and
autologous BMT recipients. Bone Marrow Transplantation
1993;11:1–5.
Ercan 2005
Ercan TE, Soycan LY, Apak H, Celkan T, Ozkan A,
Akdenizli E, et al.Antibody titers and immune response to
diphtheria-tetanus-pertussis and measles-mumps-rubella
vaccination in children treated for acute lymphoblastic
leukemia. Journal of Pediatric Hematology/Oncology 2005;
27:273–7.
Feery 1977
Feery BJ, Sullivan JR, Hurley TH, Evered MG.
Immunization with influenza vaccine in patients with
haematological malignant disease. Medical Journal of
Australia 1977;26:292–4.
Feldman 1977
Feldman S, Webster RG, Sugg M. Influenza in children and
young adults with cancer. Cancer 1977;39:350–3.
Feldman 1998
Feldman S, Andrew M, Norris M, McIntyre B, Iyer R.
Decline in rates of seropositivity for measles, mumps, and
rubella antibodies among previously immunized children
treated for acute leukemia. Clinical Infectious Diseases 1998;
27:388–90.
Fioredda 2005
Fioredda F, Giacchino M, Castagnola E. Assessment of
humoral immunity to poliomyelitis, tetanus, hepatitis B,
measles, rubella, andmumps in children after chemotherapy.
Cancer 2005;103:1758–9.
Ganz 1978
Ganz PA, Shanley JD, Cherry JD. Responses of patients
with neoplastic diseases to influenza virus vaccine. Cancer
1978;42:2244–7.
Gershon 1984
Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky
W, LaRussa P, et al.Live attenuated varicella vaccine.
Efficacy for children with leukemia in remission. JAMA
1984;252:355–62.
Gershon 1985
Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky
W, LaRussa P, et al.A multicentre trial of live attenuated
varicella vaccine in children with leukaemia in remission.
Postgraduate Medical Journal 1985;61 Suppl 4:73–8.
22Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gershon 1989
Gershon AA, Steinberg SP. Persistence of immunity to
varicella in children with leukemia immunized with live
attenuated varicella vaccine. New England Journal of
Medicine 1989;320:892–7.
Gershon 1990
Gershon AA, Steinberg SP. Live attenuated varicella vaccine:
protection in healthy adults compared with leukemic
children. Journal of Infectious Diseases 1990;161:661–6.
Gribabis 1994
Gribabis DA, Panayotidis P, Boussiotis VA, Hannoun
C, Pangalis GA. Influenza virus vaccine in B-cell chronic
lymphocytic leukemia patients. Acta Haematologica 1994;9:
115–8.
Gross 1978
Gross PA, Lee H, Wolff JA, Hall CB, Minnefore AB,
Lazicki ME. Influenza immunization in immunosuppressed
children. Journal of Pediatrics 1978;92:30–5.
Haas 1985
Haas RJ, Belohradsky B, Dickerhoff R, Eichinger K, Eife R,
Holtmann H, et al.Active immunization against varicella
of children with acute leukaemia or other malignancies on
maintenance chemotherapy. Postgraduate Medical Journal
1985;61 Suppl 4:69–72.
Hardy 1991
Hardy I, Gershon AA, Steinberg SP, LaRussa P. The
incidence of zoster after immunization with live attenuated
varicella vaccine. A study in children with leukemia.
Varicella Vaccine Collaborative Study Group. New England
Journal of Medicine 1991;325:1545–50.
Hattori 1976
Hattori A, Ihara T, Iwasa T, Kamiya H, Sakurai M, Izawa
T, et al.Use of live varicella vaccine in children with acute
leukaemia or other malignancies. Lancet 1976;2:210.
Heller 1985
Heller L, Berglund G, Ahstrom L, Hellstrand K, Wahren B.
Early results of a trial of the Oka strain varicella vaccine in
children with leukaemia or other malignancies in Sweden.
Postgraduate Medical Journal 1985;61 Suppl 4:9–83.
Henning 1997
Henning KJ, White MH, Sepkowitz KA, Armstrong D.
A national survey of immunization practices following
allogeneic bone marrow transplantation. JAMA 1997;277:
1148–51.
Hodges 1979
Hodges GR, Davis JW, Lewis HD, Jr Whittier FC, Jr
Siegel CD, Chin TD, et al.Response to influenza A vaccine
among high-risk patients. Southern Medical Journal 1979;
72:29–32.
Hsieh 2002
Hsieh YC, Lu MY, Kao CL, Chiang BL, Lin DT, Lin KS, et
al.Response to influenza vaccine in children with leukemia
undergoing chemotherapy. Journal of Formosan Medical
Association 2002;101:700–4.
Irish 1998
Irish C, Alli M, Gilham C, Joseph C, Watson J. Influenza
vaccine uptake and distribution in England and Wales, July
1989-June 1997. Health Trends 1998;30:51–5.
Jackowska 1996
Jackowska T, Brydak L, Rokicka-Milewska R, Lukowska K,
Gosk B, Rudnicka H, et al.Vaccination against influenza
in children with acute lymphoblastic leukemia. Pediatria
Polsku 1996;71:301–6.
Kamiya 1984
Kamiya H, Kato T, Isaji M, Torigoe S, Oitani K, Ito M,
et al.Immunization of acute leukemic children with a live
varicella vaccine (Oka strain). Biken Journal 1984;27:
99–102.
Konno 1984
Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiya S.
A clinical trial of live attenuated varicella vaccine (Biken) in
children with malignant diseases. Biken Journal 1984;27:
73–5.
Lange 1979
Lange B, Shapiro SA, Waldman MT, Proctor E, Arbeter A.
Antibody responses to influenza immunization of children
with acute lymphoblastic leukemia. Journal of Infectious
Diseases 1979;140:402–6.
LaRussa 1996
LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for
immunocompromised children: results of collaborative
studies in the United States and Canada. Journal of Infectious
Diseases 1996;174 Suppl 3:320–3.
Leung 2004
Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong
RP, et al.Immunogenicity of a two-dose regime of varicella
vaccine in children with cancers. European Journal of
Haematology 2004;72:353–7.
Lo 1993
Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey
G. Antibody response to a two-dose influenza vaccine
regimen in adult lymphoma patients on chemotherapy.
European Journal of Clinical Microbiology & Infectious
Diseases 1993;12:778–82.
Lou 1996
Lou J, Tan AM, Tan CK. Experience of varicella vaccination
in acute lymphoplastic leukaemia. Singapore Medical Journal
1996;37:607–10.
Matsuzaki 2005
Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara
K, Hara T. Immune response after influenza vaccination in
children with cancer. Pediatric Blood & Cancer 2005;45:
831–7.
Mazza 2005
Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I,
Chyou PH, et al.Efficacy of the influenza vaccine in patients
with malignant lymphoma. Clinical Medicine & Research
2005;3:214–20.
23Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mitus 1962
Mitus A, Holloway A, Evans AE, Enders JF. Attenuated
measles vaccine in children with acute leukemia. American
Journal of Diseases of Children 1962;103:413–8.
Moryl 2004
Moryl-Bujakowska A, Czogala M, Czogala W, Balwierz
W. The assessment of efficacy of hepatitis B prophylaxis
in children with acute lymphoblastic leukemia. Przeglad
Lekarski 2004;61 Suppl 2:85–8.
Nakagawa 1978
Nakagawa H, Katsushima N. Use of live varicella vaccine
in children with acute leukemia. Tohoku Journal of
Experimental Medicine 1978;126:393–5.
Navajas 1999
Navajas A, Astigarraga I, Fernandez-Teijeiro A, Aga M,
Redondo ML, Roig A, et al.Vaccination of chickenpox in
children with acute lymphoblastic leukaemia. Enfermedades
Infecciosas Y Microbiologia Clinica 1999;17:162–5.
Nilsson 2000
Nilsson A, Nordin M, De Milito A, Grillner L, Chiodi F,
Bjork O. Cytostatic therapy reduces the immune defense.
Children treated for leukemia have impaired immunity
against measles and rubella. Lakartidningen 2000;97:
5116–8.
Nilsson 2002
Nilsson A, De Milito A, Engstrom P, Nordin M, Narita
M, Grillner L, et al.Current chemotherapy protocols for
childhood acute lymphoblastic leukemia induce loss of
humoral immunity to viral vaccination antigens. Pediatrics
2002;109:e91.
Ninane 1985
Ninane J, Latinne D, Heremans-Bracke MT, De
Bruyere M, Cornu G. Live varicella vaccine in severely
immunodepressed children. Postgraduate Medical Journal
1985;61 Suppl 4:97–102.
Nordoy 2002
Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S,
Melby H, et al.Cancer patients undergoing chemotherapy
show adequate serological response to vaccinations against
influenza virus and Streptococcus pneumoniae. Medical
Oncology 2002;19:71–8.
Oka 1984
Oka T, Iseki K, Oka R, Sakuma S, Yoshioka H, Takahashi
M. Evaluation of varicella vaccine in childhood leukemia.
Observation over 6 years. Biken Journal 1984;27:103–9.
Ortbals 1977
Ortbals DW, Liebhaber H, Presan CA, Van Amburg AL
3rd, Lee JY. Influenza immunization of adult patients with
malignant diseases. Annals of Internal Medicine 1977;87:
552–7.
Porter 2003
Porter CC, Poehling KA, Hamilton R, Frangoul H, Cooper
WO. Influenza immunization practices among pediatric
oncologists. Journal of Pediatric Hematology Oncology 2003;
25:134–8.
Porter 2004
Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune
responses to influenza immunization in children receiving
maintenance chemotherapy for acute lymphoblastic
leukemia. Pediatric Blood & Cancer 2004;42:36–40.
Rapezzi 2003
Rapezzi D, Sticchi L, Racchi O, Mangerini R,
Ferraris AM, Gaetani GF. Influenza vaccine in chronic
lymphoproliferative disorders and multiple myeloma.
European Journal of Haematology 2003;70:225–30.
Reinhardt 2003
Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone
B. Impact of conventional chemotherapy on levels of
antibodies against vaccine-preventable diseases in children
treated for cancer. Scandinavian Journal of Infectious Diseases
2003;35:851–7.
Robertson 2000
Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson
H, Hutton K, et al.Immunogenicity of vaccination against
influenza, Streptococcus pneumoniae and Haemophilus
influenzae type B in patients with multiple myeloma. British
Journal of Cancer 2000;82:1261–5.
Schafer 1979
Schafer AI, Churchill WH, Ames P, Weinstein L. The
influence of chemotherapy on response of patients with
hematologic malignancies to influenza vaccine. Cancer
1979;43:25–30.
Shildt 1979
Shildt RA, Luedke DW, Kasai G, El-Beheri S, Laham MN.
Antibody response to influenza immunization in adult
patients with malignant disease. Cancer 1979;44:1629–35.
Slordahl 1985
Slordahl SH, Wiger D, Stromoy T, Degre M, Thorsby E,
Lie SO. Vaccination of children with malignant disease
against varicella. Postgraduate Medical Journal 1985;61
Suppl 4:85–92.
Smithson 1978
Smithson WA, Siem RA, Ritts RE, Jr, Gilchrist GS, Burgert
EO Jr, Ilstrup DM, et al.Response to influenza virus vaccine
in children receiving chemotherapy for malignancy. Journal
of Pediatrics 1978;93:632–4.
Somjee 2002
Somjee S, Pai S, Parikh P, Banavali S, Kelkar R, Advani S.
Passive active prophylaxis against Hepatitis B in children
with acute lymphoblastic leukemia. Leukemia Research
2002;26:989–92.
Steinherz 1980
Steinherz PG, Brown AE, Gross PA, Braun D, Ghavimi F,
Wollner N, et al.Influenza immunization of children with
neoplastic diseases. Cancer 1980;45:750–6.
Sterne 2009
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing
reporting biases. In: Higgins JPT, Green S editor(s).
Cochrane Handbook for Systematic Reviews of Interventions
24Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Version 5.0.2 (updated September 2009). The Cochrane
Collaboration, 2009.
Stiehm 1966
Stiehm ER, Ablin A, Kushner JH, Zoger S. Measles
vaccination in patients on immunosuppressive drugs.
Immune response to certain hematologic patients to
inactivated measles vaccine. American Journal of Disease in
Children 1966;111:191–4.
Stiver 1978
Stiver HG, Weinerman BH. Impaired serum antibody
response to inactivated influenza A and B vaccine in cancer
patients. Canadian Medical Association Journal 1978;119:
733–8.
Sumaya 1977
Sumaya CV, Williams TE, Brunell PA. Bivalent influenza
vaccine in children with cancer. Journal of Infectious Diseases
1977;136 Suppl:656–60.
Sumaya 1982
Sumaya CV, Williams TE. Persistence of antibody after the
administration of influenza vaccine to children with cancer.
Pediatrics 1982;69:226–9.
Torigoe 1981
Torigoe S, Hirai S, Oitani K, Ito M, Ihara T, Iwasa T,
et al.Application of live attenuated measles and mumps
vaccines in children with acute leukemia. Biken Journal
1981;24:147–51.
van der Velden 2001
van der Velden AM, Mulder AH, Hartkamp A, Diepersloot
RJ, van Velzen-Blad H, Biesma DH. Influenza virus
vaccination and booster in B-cell chronic lymphocytic
leukaemia patients. European Journal of Internal Medicine
2001;12:420–4.
Yetgin 2001
Yetgin S, Tunc B, Koc A, Toksoy HB, Ceyhan M, Kanra G.
Two booster dose hepatitis B virus vaccination in patients
with leukemia. Leukemia Research 2001;25:647–9.
Yeung 1992
Yeung CY, Liang DC. Varicella vaccine in children
with acute lymphoblastic leukemia and non-Hodgkin
lymphoma. Pediatric Hematology Oncology 1992;9:21–34.
Yousuf 1997
Yousuf HM, Englund J, Couch R, Rolston K, Luna M,
Goodrich J, et al.Influenza among hospitalised adults with
leukemia. Clinical Infectious Diseases 1997;24:1095–9.
Zignol 2004
Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese
F, D’Elia R, et al.Assessment of humoral immunity to
poliomyelitis, tetanus, hepatitis B, measles, rubella, and
mumps in children after chemotherapy. Cancer 2004;101:
635–41.
∗ Indicates the major publication for the study
25Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Hata 2002
Methods Design: RCT
Randomization method: Block randomization
Stratification factor: None
Setting of recruitment: Hospital
Participants Inclusion criteria: 18 to 60 years old who were seropositive for varicella-zoster virus and
who had lymphoma and were scheduled for autologous hematopoietic cell transplan-
tation within the upcoming 30 days. Eligibility criteria included lack of a response, at
least once, to standard treatment for Hodgkin’s disease or non-Hodgkin’s lymphoma or
a high risk of early recurrence.
Exclusion criteria: history of zosterwithin 12months before the transplantation, exposure
to varicella-zoster virus within 4 weeks, administration of another vaccine within 4
months, or neomycin sensitivity.
Number of subjects (intervention : comparison): 59 : 60
Number of males (intervention : comparison): 37 : 37
Age in years (intervention : comparison): (mean) 44 : 44
Underlyinghematologicalmalignancies:Hodgkin’s disease or non-Hodgkin’s lymphoma
Treatments for the underlying hematological malignancies: autologous stem cell trans-
plant
Phase of treatments: Before SCT and after SCT
Previous vaccine history: Not reported
Baseline antibody levels: 1:256 to 1:16,384 (not differ between 2 groups)
Interventions Intervention (type of vaccines): inactivated VZV vaccine
Comparison (type of control): no vaccine
Details of treatment regimes in intervention group: 0.5ml dose by subcutaneous injection
into the upper arm. A dose was given to patients in the vaccine group within 30 days
before hematopoietic-cell transplantation, regardless of the apheresis schedule, and then
again 30, 60, and 90 days after transplantation.
Details of treatment regimens in comparison group: no vaccine, conventional care
Details of co-interventions: 29 patients in the vaccine group and 28 in the control group
received intravenous or oral acyclovir for oral lesions, mucositis, or genital herpes during
the first 120 days after transplantation; the dose of intravenous acyclovir ranged from
375 to 600 mg every eight hours, and that of oral acyclovir ranged from 200 to 800 mg
five times a day. The average duration of treatment with intravenous or oral acyclovir
was 10.8 days among the vaccinated patients and 9.8 days among those who were not
vaccinated; one patient in each group was treated for more than 21 days.
Duration of FU: 12 months
Outcomes Incidence of the viral infection
Mortality due to the viral infection
All-cause mortality
Frequency of 4-fold rise of protective antibodies
Cellular immune response (mean stimulation Index at 90 days, 120 days, 6 months, 12
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Hata 2002 (Continued)
months)
Proportion of CD4 T-cells that produced TNFα at 6 months
Proportion of interferon-positive CD4 T-cells at 6 months
Frequency of systemic adverse effects
Frequency of local adverse effects
Notes Risk of bias: high
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No Blinding of treating physicians but not pa-
tients. Blinding of outcome assessors un-
known
Incomplete outcome data addressed?
All outcomes
No There were 9 drop-outs (15.3%) in the
treatment group, including 2 patients who
withdrew at 30 days for unexplained rea-
sons, 6 who did not undergo transplan-
tation after randomization and 1 who
withdrew because of disease progression.
Sixteen patients in the treatment group
(27.1%) did not complete the intended
4 doses of vaccine. There were 2 patient
withdrawals (3.3%) in the control group,
both because of no transplantation after
randomization. For individual outcomes,
the amount of missing data was variable,
and up to 67.8% for two outcomes (the
proportion of CD4+ T-cells that produced
TNF-alpha and the proportion of CD4+
T-cells that produce interferon-gamma)
Free of other bias? No The treatment groups were not compara-
ble at baseline because there were more pa-
tients with Hodgkin’s disease in the control
group, and more post-first remission NHL
patients in the intervention group
Intention-to-treat analysis? Unclear Not reported.
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Redman 1997
Methods Design: RCT
Randomization method: Stratified block randomization
Stratification factor: graft type (autologous versus allogeneic)
Setting of recruitment: Stanford University Medical Center
Participants Inclusion criteria: 18 to 49 years old scheduled to undergo SCT at Stanford University
Medical Center, and who had leukemia or lymphoma. Serological evidence of VZV
before transplantation, no history of herpes zoster, no exposure to VZV or other immu-
nization during the 1st month after SCT.
Exclusion criteria: None
Number of subjects (intervention : comparison): 1st protocol 14 : 14; 2nd protocol 24
: 23
Number of males (intervention : comparison): 1st protocol 9 : 11; 2nd protocol 13 : 11
Age in years (intervention : comparison): (mean) 1st protocol 38 : 38; 2nd protocol 34
: 39
Underlying hematological malignancies: leukemia or lymphoma
Treatments for the underlying hematological malignancies: autologous or allogeneic stem
cell transplant
Phase of treatments: 1-3 months after SCT
Previous vaccine history: Not reported
Baseline antibody levels: 1:256 to 1:16384 (no difference between 2 groups)
Interventions Intervention (type of vaccines): inactivated VZV vaccine
Comparison (type of control): no vaccine
Details of treatment regimes in intervention group: 1st protocol in 1993: single dose
(0.5ml sc) at 1month post-SCT; 2nd protocol in 1994-1995: 3 doses sc at 1, 2, 3months
post-SCT
Details of treatment regimens in comparison group: no vaccine, conventional care
Details of co-interventions: acyclovir given to all patients during HSV outbreaks. IV
ganciclovir and IVIG given to all allogeneic SCT recipients for 3 months after SCT and
all patients with CMV disease.
Duration of FU: 12 months
Outcomes Incidence of the viral infection
Mortality due to the viral infection
All-cause mortality
Mean severity score
Frequency of 4-fold rise of protective antibodies
Cellular immune response (mean stimulation Index at 3 months, 4 months, 5 months,
12 months)
Frequency of systemic adverse effects
Frequency of local adverse effects
Notes Risk of bias: high
Risk of bias
Item Authors’ judgement Description
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Redman 1997 (Continued)
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No Blinding of treating physicians but not pa-
tients. Blinding of outcome assessors un-
known
Incomplete outcome data addressed?
All outcomes
No There was no drop-out reported but miss-
ing data occurred in up to 73.9% in the
treatment and the control groups respec-
tively in one of the outcomes (post-stimu-
lation interleukin 10 concentrations at 12
months)
Free of other bias? No The treatment groupswere not comparable
at baseline because in protocol 2, there were
more CML patients in the control group
Intention-to-treat analysis? Unclear Not reported.
Esposito 2010
Methods Design: RCT
Randomization method: not reported
Stratification factor: Length of time after completion of chemotherapy (<6months versus
6-24 months)
Setting of recruitment:Pediatric Units of The Universities of Bari and Milano Bicocca,
Italy
Participants Inclusion criteria: Children >2 years who had not previously been vaccinated against
influenza, whohad completed cancer therapy for acute lymphoblastic leukemia,Hodgkin
disease or non-Hodgkin lymphoma for <2 years, and who were regularly followed up at
the two participating Oncohematologic Pediatric Units were included.
Exclusion criteria: Any serious chronic disease other than cancer (e.g., chronic pulmonary
disease including asthma, signs of cardiac or renal failure, or severe malnutrition, pro-
gressive neurological disease), Down syndrome or other known cytogenetic disorders, a
known or suspected disease of the immune system or the administration of immuno-
suppressive therapy, including systemic corticosteroids (a prednisone-equivalent dose of
2mg/kg/day) for more than 14 days, the administration of any blood product, including
immunoglobulins, in the period from 6 months before vaccination to the conclusion of
the study, the administration of a dose of influenza vaccine (commercial or investiga-
tional) before enrolment, or a documented history of hypersensitivity to any component
of the vaccine.
Number of subjects (intervention : comparison): 91 : 91
Number of males: 52 : 52
Age in years: off therapy <6 months: mean 9.7 (SD 4.3) : mean 10.1 (SD 3.9); off
therapy 6-24 months: mean 10.2 (SD 3.7) : mean 10.5 (SD 3.5)
Underlying hematological malignancies: acute lymphoblastic leukemia, Hodgkin disease
or non-Hodgkin lymphoma
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Esposito 2010 (Continued)
Treatments for the underlying hematological malignancies: chemotherapy
Phase of treatments: within 2 years after completion of chemotherapy
Previous vaccine history: no previous influenza vaccine
Baseline antibody levels: not reported
Interventions Intervention (type of vaccines): inactivated trivalent virosome-formulated subunit in-
fluenza vaccine
Comparison (type of control): no vaccine
Details of treatment regimes in intervention group:1 dose im for children >9 years, 2
doses im 30 days apart for children <9 years
Details of treatment regimens in comparison group: no vaccine
Details of co-interventions: not reported
Duration of FU: 1 influenza season
Outcomes Frequency of at least one upper respiratory tract infection
Frequency of at least one lower respiratory tract infection
Frequency of at least one infection other than influenza-like illness
Frequency of at least one hospitalization
Number of upper respiratory tract infections
Number of lower respiratory tract infections
Number of infections other than influenza-like illness
Number of days with fever
Number of antibiotics courses
Number of days lost from school
Frequency of systemic adverse effects
Frequency of local adverse effects
Notes Risk of bias: high
Other outcomes reported included measures on effectiveness of influenza vaccination
among households of the participants. These were not included in the current review
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No Blinding of treating physicians but not pa-
tients. Blinding of outcome assessors un-
known
Incomplete outcome data addressed?
All outcomes
Yes Outcomes of all participants were reported.
Free of other bias? Unclear The groups are comparable at baseline with
respect to measured characteristics. How-
ever, baseline influenza immunity is un-
known for the participants
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Esposito 2010 (Continued)
Intention-to-treat analysis? Unclear Not reported.
Musto 1997
Methods Design: RCT
Randomization method: not reported
Stratification factor: None
Setting of recruitment: IRCCS Casa Sollievo Della Sofferenza Hospital, S. Giovanni
Rotaondo, Italy
Participants Inclusion criteria: Patients with multiple myeloma and undergoing conventional che-
motherapy
Exclusion criteria: None
Number of subjects (intervention : comparison): 25 : 25
Number of males: not reported
Age in years: not reported
Underlying hematological malignancies: multiple myeloma
Treatments for the underlying hematological malignancies: chemotherapy
Phase of treatments: during chemotherapy
Previous vaccine history: not reported
Baseline antibody levels: not reported
Interventions Intervention (type of vaccines): trivalent subvirion influenza vaccine 1 dose
Comparison (type of control): no vaccine
Details of treatment regimes in intervention group: 1 dose of vaccine sc
Details of treatment regimens in comparison group: no vaccine
Details of co-interventions: not reported
Duration of FU: 4 months
Outcomes Frequency of at least one upper respiratory illnesses
Duration of febrile respiratory episodes
Frequency of hospitalizations related to respiratory illnesses
Mortality due to pneumonia
Frequency of pneumonia
Number of non-programmed visits to hospital
Frequency of local adverse effects
Notes Risk of bias: high
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No Noblinding of treating physicians, patients
or outcome assessors
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Musto 1997 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear No drop-out was reported but reported
data were insufficient to assess for amount
of missing data
Free of other bias? Unclear The treatment groups were commented to
be comparable at baseline but datawere not
provided. “There were no relevant differ-
ences between the two groups with respect
to treatments and routine clinical or labo-
ratory parameters.”
Intention-to-treat analysis? Unclear Not reported.
Ljungman 2005
Methods Design: RCT
Randomization method: not reported
Stratification factor: None
Setting of recruitment:HaematologyCentre, KarolinskaUniversityHospital, Stockholm
Participants Inclusion criteria: Patients having ongoing or recently discontinued chemotherapy
(within the last 6 months) for lymphoma, myelodysplastic syndrome (MDS), acute
leukemia, multiple myeloma or myeloproliferative disorders.
Exclusion criteria: None
Number of subjects (intervention : comparison): 2 doses (34) : 1 dose (36)
Number of males (intervention : comparison): not reported
Age in years (intervention : comparison): (median) 2 dose (59.1) : 1 dose (68.8)
Underlying hematological malignancies: lymphoma, leukemia, multiple myeloma or
Waldenstrom’s macroglobulinemia
Treatments for the underlying hematological malignancies: chemotherapy, rituximab,
alemtuzumab
Phase of treatments: during or within 6 months of chemotherapy
Previous vaccine history: not reported
Baseline antibody levels: not reported
Interventions Intervention (type of vaccines): trivalent inactivated influenza vaccine 2 doses
Comparison (type of control): trivalent inactivated influenza vaccine 1 dose
Details of treatment regimes in intervention group: 2 doses of vaccine sc 4 weeks apart
Details of treatment regimens in comparison group: 1 dose of vaccine sc
Details of co-interventions: minimum of 1 week between vaccination and the next
scheduled chemotherapy course
Duration of FU: 4 weeks
Outcomes Frequency of 4-fold rise of protective antibodies
Notes Risk of bias: high
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Ljungman 2005 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No Noblinding of treating physicians, patients
or outcome assessors
Incomplete outcome data addressed?
All outcomes
Unclear No drop-out was reported but reported
data were insufficient to assess for amount
of missing data
Free of other bias? No The treatment groupswere not comparable
at baseline because patients in the single
dose group were significantly older
Intention-to-treat analysis? Unclear Not reported.
Safdar 2006
Methods Design: RCT
Randomization method: not reported
Stratification factor: None
Setting of recruitment: adult lymphoma clinic at M.D. Anderson Cancer Center
(MDACC)
Participants Inclusion criteria: Patients with biopsy-provenNHLwhohad not received chemotherapy
in the 3 months before enrolment.
Exclusion criteria: allergic to influenza vaccine or egg products or had undergone splenec-
tomy. Individuals who had received rituximab and parenteral immunoglobulin within
the 6-month period before enrolment were also excluded. Patients who had received
systemic corticosteroids, other investigational vaccine, or anti-neoplastic medications in
the 4 weeks before enrolment were excluded.
Number of subjects (comparison : comparison): Standard vaccine (SV) : recombinant
vaccine (RV) 15µg : RV 45µg : RV 135µg = 6 : 9 : 6 : 6
Number of males (intervention : comparison): 15 overall
Age in years (intervention : comparison): (mean): 55 years overall
Underlying hematological malignancies: NHL
Treatments for the underlying hematological malignancies: chemotherapy+/- rituximab
or bortezomib; no anti-neoplastic therapy in 2 patients
Phase of treatments: at least 3 months after chemotherapy
Previous vaccine history: not reported
Baseline antibody levels: not reported
Interventions Intervention (type of vaccines): Recombinant vaccines: the recombinant HA protein
vaccine consisted of HA expressed in insect (SF9) cells by recombinant baculovirus.
The HA genes of the 3 influenza viruses contained in the vaccine (A/Panama/2007/99
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Safdar 2006 (Continued)
H3N2, A/New Caledonia/20/99 H1N1, and B/Hong Kong/330/2001) were indepen-
dently cloned into the plasmid baculovirus expression vector pPSC12. The vector con-
tained the AcNPV baculovirus polyhedron promoter, the baculovirus 61K signal pep-
tide, and flanking baculovirus DNA derived from the EcoRII fragment of AcNPV. After
confirmation of the correct sequences, the DNA sequences were inserted into AcNPV
by homologous recombination. Recombinant virus containing the respective HA genes
were then used to express the HAs in the high-yield SF9-derived insect cell line. The
vaccine was supplied at a final concentration of either 15 ug, 45 ug, or 135 ug of each
HA per 0.5-mL dose (45-ug, 135-ug, or 405-ug total doses of rHAO).
Comparison (type of control): standard vaccine: split-virus TIV from a single lot con-
taining 15 ug/0.5mL each of the HA of influenza A/Panama/2007/99(H3N2), A/New
Caledonia/20/99(H1N1), and B/Hong Kong/330/2001 (Sanofi Pasteur).
Details of treatment regimes in intervention group: 1 dose
Details of treatment regimens in comparison group: 1 dose
Details of co-interventions: not reported
Duration of FU: 4 weeks for antibody response, 6 months for safety
Outcomes Frequency of 4-fold rise of protective antibodies
Frequency of systemic adverse effects
Frequency of local adverse effects
Notes Risk of bias: moderate
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
Yes Blinding of treating physicians and pa-
tients. Blinding of outcome assessors un-
known
Incomplete outcome data addressed?
All outcomes
Yes No drop-out was reported and data on out-
comes were complete.
Free of other bias? Unclear Comparability of the treatment groups at
baseline was uncertain because baseline
data (age, gender, type of lymphoma and
treatments) of different groups were not
presented
Intention-to-treat analysis? Unclear Not reported.
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Hsieh 2002
Methods Design: RCT
Randomization method: not reported
Stratification factor: None
Setting of recruitment: Far Eastern Memorial Hospital, Taipei
Participants Inclusion criteria: Children with acute lymphoblastic leukemia in the maintenance stage
who received 6-mercaptopurine daily, methotrexate weekly, and reinduction with vin-
cristine and prednisolone every 2 months
Exclusion criteria: None
Number of subjects (intervention : comparison): 14 : 11
Number of males: total 14
Age in years: mean 7.3 years
Underlying hematological malignancies: acute lymphoblastic leukemia
Treatments for the underlying hematological malignancies: chemotherapy
Phase of treatments: during maintenance stage
Previous vaccine history: not reported
Baseline antibody levels: not reported
Interventions Intervention (protocol 1): inactivated influenza vaccine (Vaxigrip) first dose given at the
time of reinduction chemotherapy and second dose 4 weeks later
Comparison (protocol 2): inactivated influenza vaccine (Vaxigrip) first dose given 4
weeks before reinduction chemotherapy and second dose at the time of reinduction
chemotherapy
Details of treatment regimes in intervention group: 2 doses of 0.5ml Vaxigrip inactivated
influenza vaccine sc 4 weeks apart
Details of treatment regimens in comparison group: 2 doses of 0.5ml Vaxigrip inactivated
influenza vaccine sc 4 weeks apart
Details of co-interventions: 6-mercaptopurine daily, methotrexate weekly, reinduction
chemotherapy with vincristine and prednisolone every 2 months
Duration of FU: 4 weeks
Outcomes Frequency of 4-fold rise of protective antibodies
Frequency of seroconversion (increase of antibody titre from below 40 to no less than
40)
Frequency of systemic adverse effects
Frequency of local adverse effects
Notes The study includes 2 more non-randomized control groups of children with asthma and
healthy children. These control groups were excluded because they were not randomly
assigned to one of the 2 protocols
Risk of bias: high
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
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Hsieh 2002 (Continued)
Blinding?
All outcomes
No Noblinding of treating physicians, patients
or outcome assessors
Incomplete outcome data addressed?
All outcomes
No No drop-out was reported but missing data
occurred in up to 72.7% in the control
group in two of the outcomes (seroconver-
sion in influenzaA/H1antibody after 1 and
2 doses of vaccine)
Free of other bias? Unclear Comparability of the treatment groups at
baseline was uncertain because baseline
characteristics of the two groups were not
mentioned separately
Intention-to-treat analysis? Unclear Not reported.
Parkkali 1997
Methods Design: RCT
Randomization method: not reported
Stratification factor: None
Setting of recruitment: Helsinki University Central Hospital
Participants Inclusion criteria: adults (age >16 years) who had received a bone marrow transplant
from a sibling donor between January 1985 and November 1989
Exclusion criteria: not reported
Number of subjects (intervention : comparison): 23 : 22
Number of males (intervention : comparison): 12 : 12
Age in years (intervention : comparison): (median): 31 : 30 (range 16-48 : 18-49)
Underlying hematological malignancies: AML, ALL, CML, multiple myeloma, Burkitt’s
lymphoma, lymphoblastic lymphoma, severe aplastic anemia
Treatments for the underlying hematological malignancies: allogeneic matched sibling
stem cell transplant
Phase of treatments: 6-18 months post-transplant
Previous vaccine history: not reported
Baseline antibody levels: geometric mean titre (GMT) overall: PV1 (707), PV2 (1029),
PV3 (180)
Interventions Intervention (type of vaccines): Inactivated trivalent poliovirus vaccine (Polio Novum,
RIVM, Bilthoven, The Netherlands) at 6, 8 and 14 months after BMT
Comparison (type of control): Inactivated trivalent poliovirus vaccine (Polio Novum,
RIVM, Bilthoven, The Netherlands) at 18, 20 and 26 months after BMT
Details of treatment regimes in intervention group: 3 doses sc at 6, 8 and 14 months
after BMT
Details of treatment regimens in comparison group: 3 doses sc at 18, 20 and 26 months
after BMT
Details of co-interventions: Three doses of tetanus toxoid vaccine (manufactured by
National Public Health Institute, Helsinki, Finland) were given with the same sched-
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Parkkali 1997 (Continued)
ule as the polio vaccine. At the time of the first dose of polio vaccine the patients re-
ceived Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vac-
cine (ProHIBIT; Connaught Laboratories, Swiftwater, PA, USA). At the time of the
second dose of polio vaccine the recipients were immunized with pneumococcal polysac-
charide vaccine. (Pneumovax; Merck, Sharp and Dohme, West Point, PA, USA), and
with meningococcal polysaccharide vaccine (Mencevax ACW135Y; Smith Kline RIT,
Rixensart, Belgium).
Duration of FU: 22 months
Outcomes Frequency of 4-fold rise of antibody after each dose
Geometric mean titre of protective antibody after each dose
Notes Risk of bias: high
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
No No blinding of treating physicians or pa-
tients. Blinding of outcome assessors un-
known
Incomplete outcome data addressed?
All outcomes
Unclear There were 9 drop-outs (34.6%) in the
treatment group, including 2 who died be-
fore vaccinations, 1 who had not received
the vaccine and 6 losses to follow-up with
unknown reasons. Therewere 12drop-outs
(41.4%) in the control group, including
6 who died before vaccination, 1 who re-
lapsed and not vaccinated, and 5 loss to
follow-up with unknown reasons. Missing
data occurred up to 31.8% in the control
group in several outcomes (4-fold rise of
antibody titres to poliovirus type 1, 2 and
3, and geometric mean titre of poliovirus
antibody to poliovirus type 1, 2 and 3)
Free of other bias? No The treatment groupswere not comparable
at baseline because there were more CML
patients in late schedule group and there
weremore patients with chronic GVHD in
early schedule group
Intention-to-treat analysis? Unclear Not reported.
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Characteristics of ongoing studies [ordered by study ID]
NCT01016548
Trial name or title Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
Methods Open label randomized controlled trial
Participants Patients ages 20-65 years with lymphoproliferative disorder undergoing active chemotherapy or immunother-
apy at enrollment or completed within the last 3 months, or autologous or allogeneic stem cell transplant
recipient within the past 12 months
Interventions AS03-adjuvanted H1N1 pandemic influenza vaccine 2 doses versus 1 dose
Outcomes Primary outcome: seroconversion rates on day 21 and 42. Secondary outcome: adverse events to vaccination
on day 7, 21, and 28
Starting date November 2009
Contact information Location: Princess Margaret Hospital, Toronto, Ontario, Canada. Principal investigator: John Kuruvilla
Notes Completed study, pending analysis results.
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D A T A A N D A N A L Y S E S
Comparison 1. Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of herpes zoster 2 138 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.30, 1.00]
2 Mortality due to infection 2 194 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 All cause mortality 2 139 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.54, 1.69]
4 4-fold rise in VZV antibody titre 2 123 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.20, 4.52]
5 Lymphocyte stimulation index 2 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Lymphocyte stimulation
index at 1 month
1 99 Mean Difference (IV, Random, 95% CI) Not estimable
5.2 Lymphocyte stimulation
index at 3 months
2 112 Mean Difference (IV, Random, 95% CI) 7.63 [6.60, 8.66]
5.3 Lymphocyte stimulation
index at 4 months
2 120 Mean Difference (IV, Random, 95% CI) 10.92 [2.13, 19.71]
5.4 Lymphocyte stimulation
index at 5-6 months
2 111 Mean Difference (IV, Random, 95% CI) 9.72 [-3.05, 22.50]
5.5 Lymphocyte stimulation
index at 12 months
2 77 Mean Difference (IV, Random, 95% CI) 29.45 [8.51, 50.39]
6 Percentage of CD4+ T cells
producing TNF-alpha
1 38 Mean Difference (IV, Fixed, 95% CI) 31.0 [24.75, 37.25]
7 Percentage of CD4+ T cells
producing interferon-gamma
1 38 Mean Difference (IV, Fixed, 95% CI) 22.0 [16.57, 27.43]
8 Post-stimulation
interferon-gamma
concentration
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Post-stimulation
interferon-gamma
concentration at 1 month
1 29 Mean Difference (IV, Fixed, 95% CI) 8.0 [2.39, 13.61]
8.2 Post-stimulation
interferon-gamma
concentration at 2 months
1 20 Mean Difference (IV, Fixed, 95% CI) -107.00 [-206.58, -
7.42]
8.3 Post-stimulation
interferon-gamma
concentration at 3 months
1 20 Mean Difference (IV, Fixed, 95% CI) 8.0 [-56.07, 72.07]
8.4 Post-stimulation
interferon-gamma
concentration at 4 months
1 23 Mean Difference (IV, Fixed, 95% CI) 74.0 [22.75, 125.25]
8.5 Post-stimulation
interferon-gamma
concentration at 5 months
1 18 Mean Difference (IV, Fixed, 95% CI) -110.0 [-220.39,
0.39]
8.6 Post-stimulation
interferon-gamma
concentration at 12 months
1 13 Mean Difference (IV, Fixed, 95% CI) -148.0 [-305.09,
9.09]
9 Post-stimulation interleukin-10
concentration
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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9.1 Post-stimulation
interleukin-10 concentration at
1 month
1 29 Mean Difference (IV, Fixed, 95% CI) -33.0 [-56.78, -9.22]
9.2 Post-stimulation
interleukin-10 concentration at
2 months
1 20 Mean Difference (IV, Fixed, 95% CI) -39.0 [-78.31, 0.31]
9.3 Post-stimulation
interleukin-10 concentration at
3 months
1 20 Mean Difference (IV, Fixed, 95% CI) -39.0 [-84.26, 6.26]
9.4 Post-stimulation
interleukin-10 concentration at
4 months
1 23 Mean Difference (IV, Fixed, 95% CI) -54.00 [-97.22, -
14.78]
9.5 Post-stimulation
interleukin-10 concentration at
5 months
1 18 Mean Difference (IV, Fixed, 95% CI) -26.0 [-85.74,
33.74]
9.6 Post-stimulation
interleukin-10 concentration at
12 months
1 13 Mean Difference (IV, Fixed, 95% CI) -53.0 [-128.70,
22.70]
10 Frequency of systemic adverse
effects
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Frequency of all systemic
adverse effects
2 194 Risk Ratio (M-H, Fixed, 95% CI) 5.94 [0.73, 48.55]
10.2 Frequency of headache 2 194 Risk Ratio (M-H, Fixed, 95% CI) 3.97 [0.45, 34.93]
10.3 Frequency of arthralgia
or myalgia
1 75 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [0.24, 98.18]
11 Frequency of local adverse
effects
2 194 Risk Ratio (M-H, Fixed, 95% CI) 20.94 [2.88, 152.36]
12 Severity score of herpes zoster 1 10 Mean Difference (IV, Random, 95% CI) 2.60 [0.94, 4.26]
Comparison 2. Influenza vaccine versus no vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality due to infection
(pneumonia)
1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.97]
2 Incidence of complications 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Frequency of at least one
lower respiratory tract infection
2 232 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.78]
2.2 Frequency of at least
one infections other than
influenza-like illness
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.54, 1.24]
3 Rate of hospitalization 2 232 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.09, 0.31]
4 Frequency of at least one adverse
effects
2 232 Risk Ratio (M-H, Fixed, 95% CI) 35.0 [4.90, 249.80]
5 Frequency of systemic adverse
effects
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Frequency of fever 1 182 Risk Ratio (M-H, Fixed, 95% CI) 15.0 [0.87, 258.82]
5.2 Frequency of irritability 1 182 Risk Ratio (M-H, Fixed, 95% CI) 19.0 [1.12, 321.67]
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5.3 Frequency of decreased
appetite
1 182 Risk Ratio (M-H, Fixed, 95% CI) 13.0 [0.74, 227.43]
5.4 Frequency of rhinitis 1 182 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.49, 164.78]
5.5 Frequency of cough 1 182 Risk Ratio (M-H, Fixed, 95% CI) 15.0 [0.87, 258.82]
5.6 Frequency of vomiting 1 182 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 102.72]
6 Frequency of local adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Frequency of at least one
local adverse events
2 232 Risk Ratio (M-H, Fixed, 95% CI) 22.0 [3.05, 158.51]
6.2 Frequency of redness 1 182 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.37, 133.62]
6.3 Frequency of swelling or
induration
1 182 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.37, 133.62]
7 Frequency of at least one upper
respiratory infections
2 232 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.44, 0.72]
8 Number of upper respiratory
tract infections
1 182 Mean Difference (IV, Fixed, 95% CI) -1.23 [-1.52, -0.94]
9 Number of lower respiratory
tract infections
1 182 Mean Difference (IV, Fixed, 95% CI) -0.3 [-0.44, -0.16]
10 Number of infections other
than influenza-like illness
1 182 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.35, 0.15]
11 Number of days with fever 1 182 Mean Difference (IV, Fixed, 95% CI) -1.70 [-2.25, -1.15]
12 Number of antibiotics courses 1 182 Mean Difference (IV, Fixed, 95% CI) -1.85 [-2.30, -1.40]
13 Number of days lost from
school
1 182 Mean Difference (IV, Fixed, 95% CI) -4.94 [-5.65, -4.23]
Comparison 3. Influenza vaccine, two doses versus single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in influenza antibody
titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in influenza
A/H3 antibody titre
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [0.71, 5.12]
1.2 4-fold rise in influenza
A/H1 antibody titre
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.31, 2.05]
1.3 4-fold rise in influenza B
antibody titre
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.52, 2.73]
2 Antibody titre above 1:40 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Antibody titre above 1:40
for influenza A/H3
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.38, 2.28]
2.2 Antibody titre above 1:40
for influenza A/H1
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.48, 2.35]
2.3 Antibody titre above 1:40
for influenza B
1 70 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.30, 2.63]
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Comparison 4. Recombinant influenza vaccine 15 ug versus standard influenza vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in influenza
hemoagglutination inhibiting
antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in influenza
A/H3 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.23, 4.31]
1.2 4-fold rise in influenza
A/H1 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.01, 4.93]
1.3 4-fold rise in influenza B
antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.91]
2 4-fold rise in influenza
neutralizing antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 4-fold rise in influenza
A/H3 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 2.67 [0.39, 18.42]
2.2 4-fold rise in influenza
A/H1 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.91]
2.3 4-fold rise in influenza B
antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.91]
3 4-fold rise in influenza antibody
titre (either hemoagglutination
inhibiting or neutralizing)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 4-fold rise in influenza
A/H3 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.35, 5.13]
3.2 4-fold rise in influenza
A/H1 antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.91]
3.3 4-fold rise in influenza B
antibody titre
1 15 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.91]
Comparison 5. Recombinant influenza vaccine 45 ug versus standard influenza vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in influenza
hemoagglutination inhibiting
antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.06, 4.15]
1.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.08, 12.56]
1.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.46]
2 4-fold rise in influenza
neutralizing antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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2.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 4.33 [1.03, 18.17]
2.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.38, 6.00]
2.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.46]
3 4-fold rise in influenza antibody
titre (either hemoagglutination
inhibiting or neutralizing)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.38, 6.00]
3.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.38, 6.00]
3.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.46]
Comparison 6. Recombinant influenza vaccine 135 ug versus standard influenza vaccine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in influenza
hemoagglutination inhibiting
antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.38, 6.00]
1.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.08, 12.56]
1.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.20, 4.95]
2 4-fold rise in influenza
neutralizing antibody titre
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.42, 21.30]
2.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.20, 4.95]
2.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.20, 4.95]
3 4-fold rise in influenza antibody
titre (either hemoagglutination
inhibiting or neutralizing)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 4-fold rise in influenza
A/H3 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.38, 6.00]
3.2 4-fold rise in influenza
A/H1 antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.20, 4.95]
3.3 4-fold rise in influenza B
antibody titre
1 12 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.20, 4.95]
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Comparison 7. Comparison of different influenza vaccine schedules: first dose versus second dose given with re-
induction
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in influenza antibody
titre after first vaccine dose
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in influenza
A/H3 antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.36, 1.30]
1.2 4-fold rise in influenza
A/H1 antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 7.20 [0.43, 120.96]
1.3 4-fold rise in influenza B
antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.39, 2.29]
2 4-fold rise in influenza antibody
titre after second vaccine dose
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 4-fold rise in influenza
A/H3 antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.48, 1.70]
2.2 4-fold rise in influenza
A/H1 antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 3.93 [0.53, 28.93]
2.3 4-fold rise in influenza B
antibody titre
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.39, 2.29]
3 Seroconversion after first vaccine
dose (increase of antibody titre
from <40 to >=40)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Seroconversion in
influenza A/H3 antibody
1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.64, 1.64]
3.2 Seroconversion in
influenza A/H1 antibody
1 10 Risk Ratio (M-H, Fixed, 95% CI) 2.5 [0.15, 40.67]
3.3 Seroconversion in
influenza B antibody
1 14 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.37, 2.33]
4 Seroconversion after second
vaccine dose (increase of
antibody titre from <40 to
>=40)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Seroconversion in
influenza A/H3 antibody
1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.64, 1.64]
4.2 Seroconversion in
influenza A/H1 antibody
1 10 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.40, 11.35]
4.3 Seroconversion in
influenza B antibody
1 14 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.37, 2.33]
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Comparison 8. Inactivated poliovirus vaccine early schedule versus late schedule
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 4-fold rise in poliovirus antibody
titre after first vaccine dose
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 4-fold rise in poliovirus
type 1 antibody titre
1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.20, 1.01]
1.2 4-fold rise in poliovirus
type 2 antibody titre
1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.15, 0.80]
1.3 4-fold rise in poliovirus
type 3 antibody titre
1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.34, 0.96]
2 4-fold rise in poliovirus antibody
titre after second vaccine dose
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 4-fold rise in poliovirus
type 1 antibody titre
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.34, 1.05]
2.2 4-fold rise in poliovirus
type 2 antibody titre
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.34, 1.05]
2.3 4-fold rise in poliovirus
type 3 antibody titre
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.48, 1.01]
3 4-fold rise in poliovirus antibody
titre after third vaccine dose
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 4-fold rise in poliovirus
type 1 antibody titre
1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.45, 1.13]
3.2 4-fold rise in poliovirus
type 2 antibody titre
1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.41, 1.16]
3.3 4-fold rise in poliovirus
type 3 antibody titre
1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.09]
Analysis 1.1. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 1 Incidence
of herpes zoster.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 1 Incidence of herpes zoster
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hata 2002 7/53 19/58 79.0 % 0.40 [ 0.18, 0.88 ]
Redman 1997 5/13 5/14 21.0 % 1.08 [ 0.40, 2.88 ]
Total (95% CI) 66 72 100.0 % 0.54 [ 0.30, 1.00 ]
Total events: 12 (Intervention), 24 (Control)
Heterogeneity: Chi2 = 2.41, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.97 (P = 0.049)
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours control
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Analysis 1.2. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 2 Mortality
due to infection.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 2 Mortality due to infection
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hata 2002 0/59 0/60 0.0 [ 0.0, 0.0 ]
Redman 1997 0/38 0/37 0.0 [ 0.0, 0.0 ]
Total (95% CI) 97 97 0.0 [ 0.0, 0.0 ]
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours intervention Favours control
Analysis 1.3. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 3 All cause
mortality.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 3 All cause mortality
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hata 2002 12/53 16/58 83.6 % 0.82 [ 0.43, 1.57 ]
Redman 1997 5/14 3/14 16.4 % 1.67 [ 0.49, 5.67 ]
Total (95% CI) 67 72 100.0 % 0.96 [ 0.54, 1.69 ]
Total events: 17 (Intervention), 19 (Control)
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 0.14 (P = 0.89)
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours control
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Analysis 1.4. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 4 4-fold rise
in VZV antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 4 4-fold rise in VZV antibody titre
Study or subgroup Intervention Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hata 2002 3/49 3/47 0.96 [ 0.20, 4.52 ]
Redman 1997 0/13 0/14 0.0 [ 0.0, 0.0 ]
Total (95% CI) 62 61 0.96 [ 0.20, 4.52 ]
Total events: 3 (Intervention), 3 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 1.5. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 5
Lymphocyte stimulation index.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 5 Lymphocyte stimulation index
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Lymphocyte stimulation index at 1 month
Hata 2002 49 6.7 (1) 50 6.7 (2.67) 100.0 % 0.0 [ -0.79, 0.79 ]
Subtotal (95% CI) 49 50 100.0 % 0.0 [ -0.79, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Lymphocyte stimulation index at 3 months
Hata 2002 42 15.7 (3.47) 43 8 (1.63) 78.7 % 7.70 [ 6.54, 8.86 ]
Redman 1997 13 12.2 (3.13) 14 4.83 (2.74) 21.3 % 7.37 [ 5.14, 9.60 ]
Subtotal (95% CI) 55 57 100.0 % 7.63 [ 6.60, 8.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 14.57 (P < 0.00001)
3 Lymphocyte stimulation index at 4 months
Hata 2002 39 22.5 (3.8) 34 7.1 (2.3) 50.1 % 15.40 [ 13.98, 16.82 ]
Redman 1997 24 8.43 (3.89) 23 2 (0.33) 49.9 % 6.43 [ 4.87, 7.99 ]
Subtotal (95% CI) 63 57 100.0 % 10.92 [ 2.13, 19.71 ]
Heterogeneity: Tau2 = 39.65; Chi2 = 69.30, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 2.44 (P = 0.015)
4 Lymphocyte stimulation index at 5-6 months
Hata 2002 34 27.3 (6.1) 30 11 (5.3) 49.6 % 16.30 [ 13.51, 19.09 ]
Redman 1997 24 8.56 (2.81) 23 5.3 (2.47) 50.4 % 3.26 [ 1.75, 4.77 ]
Subtotal (95% CI) 58 53 100.0 % 9.72 [ -3.05, 22.50 ]
Heterogeneity: Tau2 = 83.71; Chi2 = 64.78, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.49 (P = 0.14)
5 Lymphocyte stimulation index at 12 months
Hata 2002 33 42.8 (8.3) 27 21.3 (5.9) 64.4 % 21.50 [ 17.90, 25.10 ]
Redman 1997 8 53.4 (34.09) 9 9.59 (3.42) 35.6 % 43.81 [ 20.08, 67.54 ]
Subtotal (95% CI) 41 36 100.0 % 29.45 [ 8.51, 50.39 ]
Heterogeneity: Tau2 = 173.90; Chi2 = 3.32, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 2.76 (P = 0.0058)
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Analysis 1.6. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 6
Percentage of CD4+ T cells producing TNF-alpha.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 6 Percentage of CD4+ T cells producing TNF-alpha
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hata 2002 19 50 (12) 19 19 (7) 100.0 % 31.00 [ 24.75, 37.25 ]
Total (95% CI) 19 19 100.0 % 31.00 [ 24.75, 37.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.73 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 7
Percentage of CD4+ T cells producing interferon-gamma.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 7 Percentage of CD4+ T cells producing interferon-gamma
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hata 2002 19 33 (11) 19 11 (5) 100.0 % 22.00 [ 16.57, 27.43 ]
Total (95% CI) 19 19 100.0 % 22.00 [ 16.57, 27.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 8 Post-
stimulation interferon-gamma concentration.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 8 Post-stimulation interferon-gamma concentration
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Post-stimulation interferon-gamma concentration at 1 month
Redman 1997 14 30 (9) 15 22 (6) 100.0 % 8.00 [ 2.39, 13.61 ]
Subtotal (95% CI) 14 15 100.0 % 8.00 [ 2.39, 13.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0052)
2 Post-stimulation interferon-gamma concentration at 2 months
Redman 1997 12 54 (27) 8 161 (142) 100.0 % -107.00 [ -206.58, -7.42 ]
Subtotal (95% CI) 12 8 100.0 % -107.00 [ -206.58, -7.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
3 Post-stimulation interferon-gamma concentration at 3 months
Redman 1997 12 149 (84) 8 141 (62) 100.0 % 8.00 [ -56.07, 72.07 ]
Subtotal (95% CI) 12 8 100.0 % 8.00 [ -56.07, 72.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
4 Post-stimulation interferon-gamma concentration at 4 months
Redman 1997 10 142 (81) 13 68 (19) 100.0 % 74.00 [ 22.75, 125.25 ]
Subtotal (95% CI) 10 13 100.0 % 74.00 [ 22.75, 125.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0047)
5 Post-stimulation interferon-gamma concentration at 5 months
Redman 1997 10 121 (60) 8 231 (150) 100.0 % -110.00 [ -220.39, 0.39 ]
Subtotal (95% CI) 10 8 100.0 % -110.00 [ -220.39, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
6 Post-stimulation interferon-gamma concentration at 12 months
Redman 1997 7 166 (71) 6 314 (185) 100.0 % -148.00 [ -305.09, 9.09 ]
Subtotal (95% CI) 7 6 100.0 % -148.00 [ -305.09, 9.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
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Analysis 1.9. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 9 Post-
stimulation interleukin-10 concentration.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 9 Post-stimulation interleukin-10 concentration
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Post-stimulation interleukin-10 concentration at 1 month
Redman 1997 14 116 (28) 15 149 (37) 100.0 % -33.00 [ -56.78, -9.22 ]
Subtotal (95% CI) 14 15 100.0 % -33.00 [ -56.78, -9.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
2 Post-stimulation interleukin-10 concentration at 2 months
Redman 1997 12 125 (35) 8 164 (49) 100.0 % -39.00 [ -78.31, 0.31 ]
Subtotal (95% CI) 12 8 100.0 % -39.00 [ -78.31, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
3 Post-stimulation interleukin-10 concentration at 3 months
Redman 1997 12 111 (45) 8 150 (54) 100.0 % -39.00 [ -84.26, 6.26 ]
Subtotal (95% CI) 12 8 100.0 % -39.00 [ -84.26, 6.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
4 Post-stimulation interleukin-10 concentration at 4 months
Redman 1997 10 138 (50) 13 194 (50) 100.0 % -56.00 [ -97.22, -14.78 ]
Subtotal (95% CI) 10 13 100.0 % -56.00 [ -97.22, -14.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
5 Post-stimulation interleukin-10 concentration at 5 months
Redman 1997 10 121 (53) 8 147 (72) 100.0 % -26.00 [ -85.74, 33.74 ]
Subtotal (95% CI) 10 8 100.0 % -26.00 [ -85.74, 33.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
6 Post-stimulation interleukin-10 concentration at 12 months
Redman 1997 7 163 (65) 6 216 (73) 100.0 % -53.00 [ -128.70, 22.70 ]
Subtotal (95% CI) 7 6 100.0 % -53.00 [ -128.70, 22.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 1.10. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 10
Frequency of systemic adverse effects.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 10 Frequency of systemic adverse effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Frequency of all systemic adverse effects
Hata 2002 1/59 0/60 49.5 % 3.05 [ 0.13, 73.39 ]
Redman 1997 4/38 0/37 50.5 % 8.77 [ 0.49, 157.38 ]
Subtotal (95% CI) 97 97 100.0 % 5.94 [ 0.73, 48.55 ]
Total events: 5 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
2 Frequency of headache
Hata 2002 1/59 0/60 49.5 % 3.05 [ 0.13, 73.39 ]
Redman 1997 2/38 0/37 50.5 % 4.87 [ 0.24, 98.18 ]
Subtotal (95% CI) 97 97 100.0 % 3.97 [ 0.45, 34.93 ]
Total events: 3 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
3 Frequency of arthralgia or myalgia
Redman 1997 2/38 0/37 100.0 % 4.87 [ 0.24, 98.18 ]
Subtotal (95% CI) 38 37 100.0 % 4.87 [ 0.24, 98.18 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 1.11. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 11
Frequency of local adverse effects.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 11 Frequency of local adverse effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hata 2002 12/59 0/60 49.5 % 25.42 [ 1.54, 419.70 ]
Redman 1997 8/38 0/37 50.5 % 16.56 [ 0.99, 277.05 ]
Total (95% CI) 97 97 100.0 % 20.94 [ 2.88, 152.36 ]
Total events: 20 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine, Outcome 12
Severity score of herpes zoster.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 1 Varicella zoster vaccine (VZV) vaccine versus no vaccine
Outcome: 12 Severity score of herpes zoster
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Redman 1997 5 11 (1.8) 5 8.4 (0.6) 100.0 % 2.60 [ 0.94, 4.26 ]
Total (95% CI) 5 5 100.0 % 2.60 [ 0.94, 4.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.06 (P = 0.0022)
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Analysis 2.1. Comparison 2 Influenza vaccine versus no vaccine, Outcome 1 Mortality due to infection
(pneumonia).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 1 Mortality due to infection (pneumonia)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Musto 1997 0/25 2/25 100.0 % 0.20 [ 0.01, 3.97 ]
Total (95% CI) 25 25 100.0 % 0.20 [ 0.01, 3.97 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
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Analysis 2.2. Comparison 2 Influenza vaccine versus no vaccine, Outcome 2 Incidence of complications.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 2 Incidence of complications
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Frequency of at least one lower respiratory tract infection
Esposito 2010 9/91 20/91 81.6 % 0.45 [ 0.22, 0.93 ]
Musto 1997 0/25 4/25 18.4 % 0.11 [ 0.01, 1.96 ]
Subtotal (95% CI) 116 116 100.0 % 0.39 [ 0.19, 0.78 ]
Total events: 9 (Intervention), 24 (Control)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0082)
2 Frequency of at least one infections other than influenza-like illness
Esposito 2010 27/91 33/91 100.0 % 0.82 [ 0.54, 1.24 ]
Subtotal (95% CI) 91 91 100.0 % 0.82 [ 0.54, 1.24 ]
Total events: 27 (Intervention), 33 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
0.01 0.1 1 10 100
Favours intervention Favours control
54Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Influenza vaccine versus no vaccine, Outcome 3 Rate of hospitalization.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 3 Rate of hospitalization
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Esposito 2010 8/91 48/91 80.0 % 0.17 [ 0.08, 0.33 ]
Musto 1997 2/25 12/25 20.0 % 0.17 [ 0.04, 0.67 ]
Total (95% CI) 116 116 100.0 % 0.17 [ 0.09, 0.31 ]
Total events: 10 (Intervention), 60 (Control)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 5.68 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Influenza vaccine versus no vaccine, Outcome 4 Frequency of at least one
adverse effects.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 4 Frequency of at least one adverse effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Esposito 2010 19/91 0/91 50.0 % 39.00 [ 2.39, 636.36 ]
Musto 1997 15/25 0/25 50.0 % 31.00 [ 1.96, 491.36 ]
Total (95% CI) 116 116 100.0 % 35.00 [ 4.90, 249.80 ]
Total events: 34 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00039)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Influenza vaccine versus no vaccine, Outcome 5 Frequency of systemic adverse
effects.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 5 Frequency of systemic adverse effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Frequency of fever
Esposito 2010 7/91 0/91 100.0 % 15.00 [ 0.87, 258.82 ]
Subtotal (95% CI) 91 91 100.0 % 15.00 [ 0.87, 258.82 ]
Total events: 7 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.062)
2 Frequency of irritability
Esposito 2010 9/91 0/91 100.0 % 19.00 [ 1.12, 321.67 ]
Subtotal (95% CI) 91 91 100.0 % 19.00 [ 1.12, 321.67 ]
Total events: 9 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
3 Frequency of decreased appetite
Esposito 2010 6/91 0/91 100.0 % 13.00 [ 0.74, 227.43 ]
Subtotal (95% CI) 91 91 100.0 % 13.00 [ 0.74, 227.43 ]
Total events: 6 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
4 Frequency of rhinitis
Esposito 2010 4/91 0/91 100.0 % 9.00 [ 0.49, 164.78 ]
Subtotal (95% CI) 91 91 100.0 % 9.00 [ 0.49, 164.78 ]
Total events: 4 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
5 Frequency of cough
Esposito 2010 7/91 0/91 100.0 % 15.00 [ 0.87, 258.82 ]
Subtotal (95% CI) 91 91 100.0 % 15.00 [ 0.87, 258.82 ]
Total events: 7 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.062)
6 Frequency of vomiting
Esposito 2010 2/91 0/91 100.0 % 5.00 [ 0.24, 102.72 ]
Subtotal (95% CI) 91 91 100.0 % 5.00 [ 0.24, 102.72 ]
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
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Analysis 2.6. Comparison 2 Influenza vaccine versus no vaccine, Outcome 6 Frequency of local adverse
effects.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 6 Frequency of local adverse effects
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Frequency of at least one local adverse events
Esposito 2010 6/91 0/91 50.0 % 13.00 [ 0.74, 227.43 ]
Musto 1997 15/25 0/25 50.0 % 31.00 [ 1.96, 491.36 ]
Subtotal (95% CI) 116 116 100.0 % 22.00 [ 3.05, 158.51 ]
Total events: 21 (Intervention), 0 (Control)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
2 Frequency of redness
Esposito 2010 3/91 0/91 100.0 % 7.00 [ 0.37, 133.62 ]
Subtotal (95% CI) 91 91 100.0 % 7.00 [ 0.37, 133.62 ]
Total events: 3 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
3 Frequency of swelling or induration
Esposito 2010 3/91 0/91 100.0 % 7.00 [ 0.37, 133.62 ]
Subtotal (95% CI) 91 91 100.0 % 7.00 [ 0.37, 133.62 ]
Total events: 3 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
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Analysis 2.7. Comparison 2 Influenza vaccine versus no vaccine, Outcome 7 Frequency of at least one
upper respiratory infections.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 7 Frequency of at least one upper respiratory infections
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Esposito 2010 39/91 66/91 78.6 % 0.59 [ 0.45, 0.77 ]
Musto 1997 8/25 18/25 21.4 % 0.44 [ 0.24, 0.83 ]
Total (95% CI) 116 116 100.0 % 0.56 [ 0.44, 0.72 ]
Total events: 47 (Intervention), 84 (Control)
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 4.60 (P < 0.00001)
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Analysis 2.8. Comparison 2 Influenza vaccine versus no vaccine, Outcome 8 Number of upper respiratory
tract infections.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 8 Number of upper respiratory tract infections
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 0.49 (0.76) 91 1.72 (1.18) 100.0 % -1.23 [ -1.52, -0.94 ]
Total (95% CI) 91 91 100.0 % -1.23 [ -1.52, -0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.36 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Influenza vaccine versus no vaccine, Outcome 9 Number of lower respiratory
tract infections.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 9 Number of lower respiratory tract infections
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 0.12 (0.23) 91 0.42 (0.62) 100.0 % -0.30 [ -0.44, -0.16 ]
Total (95% CI) 91 91 100.0 % -0.30 [ -0.44, -0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Influenza vaccine versus no vaccine, Outcome 10 Number of infections other
than influenza-like illness.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 10 Number of infections other than influenza-like illness
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 0.45 (0.77) 91 0.55 (0.92) 100.0 % -0.10 [ -0.35, 0.15 ]
Total (95% CI) 91 91 100.0 % -0.10 [ -0.35, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Influenza vaccine versus no vaccine, Outcome 11 Number of days with fever.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 11 Number of days with fever
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 1.52 (1.78) 91 3.22 (1.97) 100.0 % -1.70 [ -2.25, -1.15 ]
Total (95% CI) 91 91 100.0 % -1.70 [ -2.25, -1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.11 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Influenza vaccine versus no vaccine, Outcome 12 Number of antibiotics
courses.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 12 Number of antibiotics courses
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 0.45 (0.99) 91 2.3 (1.93) 100.0 % -1.85 [ -2.30, -1.40 ]
Total (95% CI) 91 91 100.0 % -1.85 [ -2.30, -1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.14 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Influenza vaccine versus no vaccine, Outcome 13 Number of days lost from
school.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 2 Influenza vaccine versus no vaccine
Outcome: 13 Number of days lost from school
Study or subgroup Intervention Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Esposito 2010 91 1.35 (1.71) 91 6.29 (2.98) 100.0 % -4.94 [ -5.65, -4.23 ]
Total (95% CI) 91 91 100.0 % -4.94 [ -5.65, -4.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.72 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Influenza vaccine, two doses versus single dose, Outcome 1 4-fold rise in
influenza antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 3 Influenza vaccine, two doses versus single dose
Outcome: 1 4-fold rise in influenza antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Ljungman 2005 9/34 5/36 100.0 % 1.91 [ 0.71, 5.12 ]
Subtotal (95% CI) 34 36 100.0 % 1.91 [ 0.71, 5.12 ]
Total events: 9 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 4-fold rise in influenza A/H1 antibody titre
Ljungman 2005 6/34 8/36 100.0 % 0.79 [ 0.31, 2.05 ]
Subtotal (95% CI) 34 36 100.0 % 0.79 [ 0.31, 2.05 ]
Total events: 6 (Intervention), 8 (Control)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.48 (P = 0.63)
3 4-fold rise in influenza B antibody titre
Ljungman 2005 9/34 8/36 100.0 % 1.19 [ 0.52, 2.73 ]
Subtotal (95% CI) 34 36 100.0 % 1.19 [ 0.52, 2.73 ]
Total events: 9 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 3.2. Comparison 3 Influenza vaccine, two doses versus single dose, Outcome 2 Antibody titre
above 1:40.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 3 Influenza vaccine, two doses versus single dose
Outcome: 2 Antibody titre above 1:40
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibody titre above 1:40 for influenza A/H3
Ljungman 2005 7/34 8/36 100.0 % 0.93 [ 0.38, 2.28 ]
Subtotal (95% CI) 34 36 100.0 % 0.93 [ 0.38, 2.28 ]
Total events: 7 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
2 Antibody titre above 1:40 for influenza A/H1
Ljungman 2005 9/34 9/36 100.0 % 1.06 [ 0.48, 2.35 ]
Subtotal (95% CI) 34 36 100.0 % 1.06 [ 0.48, 2.35 ]
Total events: 9 (Intervention), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
3 Antibody titre above 1:40 for influenza B
Ljungman 2005 5/34 6/36 100.0 % 0.88 [ 0.30, 2.63 ]
Subtotal (95% CI) 34 36 100.0 % 0.88 [ 0.30, 2.63 ]
Total events: 5 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
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Analysis 4.1. Comparison 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine,
Outcome 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine
Outcome: 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 3/9 2/6 100.0 % 1.00 [ 0.23, 4.31 ]
Subtotal (95% CI) 9 6 100.0 % 1.00 [ 0.23, 4.31 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 0/9 1/6 100.0 % 0.23 [ 0.01, 4.93 ]
Subtotal (95% CI) 9 6 100.0 % 0.23 [ 0.01, 4.93 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
3 4-fold rise in influenza B antibody titre
Safdar 2006 1/9 2/6 100.0 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 9 6 100.0 % 0.33 [ 0.04, 2.91 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.01 0.1 1 10 100
Favours control Favours intervention
64Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine,
Outcome 2 4-fold rise in influenza neutralizing antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine
Outcome: 2 4-fold rise in influenza neutralizing antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 4/9 1/6 100.0 % 2.67 [ 0.39, 18.42 ]
Subtotal (95% CI) 9 6 100.0 % 2.67 [ 0.39, 18.42 ]
Total events: 4 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 1/9 2/6 100.0 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 9 6 100.0 % 0.33 [ 0.04, 2.91 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 4-fold rise in influenza B antibody titre
Safdar 2006 1/9 2/6 100.0 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 9 6 100.0 % 0.33 [ 0.04, 2.91 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 4.3. Comparison 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine,
Outcome 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 4 Recombinant influenza vaccine 15 ug versus standard influenza vaccine
Outcome: 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 4/9 2/6 100.0 % 1.33 [ 0.35, 5.13 ]
Subtotal (95% CI) 9 6 100.0 % 1.33 [ 0.35, 5.13 ]
Total events: 4 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 1/9 2/6 100.0 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 9 6 100.0 % 0.33 [ 0.04, 2.91 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
3 4-fold rise in influenza B antibody titre
Safdar 2006 1/9 2/6 100.0 % 0.33 [ 0.04, 2.91 ]
Subtotal (95% CI) 9 6 100.0 % 0.33 [ 0.04, 2.91 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 5.1. Comparison 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine,
Outcome 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine
Outcome: 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 1/6 2/6 100.0 % 0.50 [ 0.06, 4.15 ]
Subtotal (95% CI) 6 6 100.0 % 0.50 [ 0.06, 4.15 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 1/6 1/6 100.0 % 1.00 [ 0.08, 12.56 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.08, 12.56 ]
Total events: 1 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 4-fold rise in influenza B antibody titre
Safdar 2006 0/6 2/6 100.0 % 0.20 [ 0.01, 3.46 ]
Subtotal (95% CI) 6 6 100.0 % 0.20 [ 0.01, 3.46 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
0.01 0.1 1 10 100
Favours control Favours intervention
67Vaccines for prophylaxis of viral infections in patients with hematological malignancies (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine,
Outcome 2 4-fold rise in influenza neutralizing antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine
Outcome: 2 4-fold rise in influenza neutralizing antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 6/6 1/6 100.0 % 4.33 [ 1.03, 18.17 ]
Subtotal (95% CI) 6 6 100.0 % 4.33 [ 1.03, 18.17 ]
Total events: 6 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 3/6 2/6 100.0 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 6 6 100.0 % 1.50 [ 0.38, 6.00 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 4-fold rise in influenza B antibody titre
Safdar 2006 0/6 2/6 100.0 % 0.20 [ 0.01, 3.46 ]
Subtotal (95% CI) 6 6 100.0 % 0.20 [ 0.01, 3.46 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 5.3. Comparison 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine,
Outcome 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 5 Recombinant influenza vaccine 45 ug versus standard influenza vaccine
Outcome: 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 3/6 2/6 100.0 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 6 6 100.0 % 1.50 [ 0.38, 6.00 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 3/6 2/6 100.0 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 6 6 100.0 % 1.50 [ 0.38, 6.00 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 4-fold rise in influenza B antibody titre
Safdar 2006 0/6 2/6 100.0 % 0.20 [ 0.01, 3.46 ]
Subtotal (95% CI) 6 6 100.0 % 0.20 [ 0.01, 3.46 ]
Total events: 0 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 6.1. Comparison 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine,
Outcome 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine
Outcome: 1 4-fold rise in influenza hemoagglutination inhibiting antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 3/6 2/6 100.0 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 6 6 100.0 % 1.50 [ 0.38, 6.00 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 1/6 1/6 100.0 % 1.00 [ 0.08, 12.56 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.08, 12.56 ]
Total events: 1 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 4-fold rise in influenza B antibody titre
Safdar 2006 2/6 2/6 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.20, 4.95 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.2. Comparison 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine,
Outcome 2 4-fold rise in influenza neutralizing antibody titre.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine
Outcome: 2 4-fold rise in influenza neutralizing antibody titre
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 3/6 1/6 100.0 % 3.00 [ 0.42, 21.30 ]
Subtotal (95% CI) 6 6 100.0 % 3.00 [ 0.42, 21.30 ]
Total events: 3 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 2/6 2/6 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.20, 4.95 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 4-fold rise in influenza B antibody titre
Safdar 2006 2/6 2/6 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.20, 4.95 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.3. Comparison 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine,
Outcome 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 6 Recombinant influenza vaccine 135 ug versus standard influenza vaccine
Outcome: 3 4-fold rise in influenza antibody titre (either hemoagglutination inhibiting or neutralizing)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Safdar 2006 3/6 2/6 100.0 % 1.50 [ 0.38, 6.00 ]
Subtotal (95% CI) 6 6 100.0 % 1.50 [ 0.38, 6.00 ]
Total events: 3 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 4-fold rise in influenza A/H1 antibody titre
Safdar 2006 2/6 2/6 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.20, 4.95 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 4-fold rise in influenza B antibody titre
Safdar 2006 2/6 2/6 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 6 6 100.0 % 1.00 [ 0.20, 4.95 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 7.1. Comparison 7 Comparison of different influenza vaccine schedules: first dose versus second
dose given with re-induction, Outcome 1 4-fold rise in influenza antibody titre after first vaccine dose.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 7 Comparison of different influenza vaccine schedules: first dose versus second dose given with re-induction
Outcome: 1 4-fold rise in influenza antibody titre after first vaccine dose
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Hsieh 2002 7/14 8/11 100.0 % 0.69 [ 0.36, 1.30 ]
Subtotal (95% CI) 14 11 100.0 % 0.69 [ 0.36, 1.30 ]
Total events: 7 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
2 4-fold rise in influenza A/H1 antibody titre
Hsieh 2002 4/14 0/11 100.0 % 7.20 [ 0.43, 120.96 ]
Subtotal (95% CI) 14 11 100.0 % 7.20 [ 0.43, 120.96 ]
Total events: 4 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
3 4-fold rise in influenza B antibody titre
Hsieh 2002 6/14 5/11 100.0 % 0.94 [ 0.39, 2.29 ]
Subtotal (95% CI) 14 11 100.0 % 0.94 [ 0.39, 2.29 ]
Total events: 6 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 7.2. Comparison 7 Comparison of different influenza vaccine schedules: first dose versus second
dose given with re-induction, Outcome 2 4-fold rise in influenza antibody titre after second vaccine dose.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 7 Comparison of different influenza vaccine schedules: first dose versus second dose given with re-induction
Outcome: 2 4-fold rise in influenza antibody titre after second vaccine dose
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in influenza A/H3 antibody titre
Hsieh 2002 8/14 7/11 100.0 % 0.90 [ 0.48, 1.70 ]
Subtotal (95% CI) 14 11 100.0 % 0.90 [ 0.48, 1.70 ]
Total events: 8 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 4-fold rise in influenza A/H1 antibody titre
Hsieh 2002 5/14 1/11 100.0 % 3.93 [ 0.53, 28.93 ]
Subtotal (95% CI) 14 11 100.0 % 3.93 [ 0.53, 28.93 ]
Total events: 5 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 4-fold rise in influenza B antibody titre
Hsieh 2002 6/14 5/11 100.0 % 0.94 [ 0.39, 2.29 ]
Subtotal (95% CI) 14 11 100.0 % 0.94 [ 0.39, 2.29 ]
Total events: 6 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 7.3. Comparison 7 Comparison of different influenza vaccine schedules: first dose versus second
dose given with re-induction, Outcome 3 Seroconversion after first vaccine dose (increase of antibody titre
from <40 to >=40).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 7 Comparison of different influenza vaccine schedules: first dose versus second dose given with re-induction
Outcome: 3 Seroconversion after first vaccine dose (increase of antibody titre from <40 to >=40)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Seroconversion in influenza A/H3 antibody
Hsieh 2002 6/7 5/6 100.0 % 1.03 [ 0.64, 1.64 ]
Subtotal (95% CI) 7 6 100.0 % 1.03 [ 0.64, 1.64 ]
Total events: 6 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 Seroconversion in influenza A/H1 antibody
Hsieh 2002 2/7 0/3 100.0 % 2.50 [ 0.15, 40.67 ]
Subtotal (95% CI) 7 3 100.0 % 2.50 [ 0.15, 40.67 ]
Total events: 2 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Seroconversion in influenza B antibody
Hsieh 2002 5/9 3/5 100.0 % 0.93 [ 0.37, 2.33 ]
Subtotal (95% CI) 9 5 100.0 % 0.93 [ 0.37, 2.33 ]
Total events: 5 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 7.4. Comparison 7 Comparison of different influenza vaccine schedules: first dose versus second
dose given with re-induction, Outcome 4 Seroconversion after second vaccine dose (increase of antibody titre
from <40 to >=40).
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 7 Comparison of different influenza vaccine schedules: first dose versus second dose given with re-induction
Outcome: 4 Seroconversion after second vaccine dose (increase of antibody titre from <40 to >=40)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Seroconversion in influenza A/H3 antibody
Hsieh 2002 6/7 5/6 100.0 % 1.03 [ 0.64, 1.64 ]
Subtotal (95% CI) 7 6 100.0 % 1.03 [ 0.64, 1.64 ]
Total events: 6 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 Seroconversion in influenza A/H1 antibody
Hsieh 2002 5/7 1/3 100.0 % 2.14 [ 0.40, 11.35 ]
Subtotal (95% CI) 7 3 100.0 % 2.14 [ 0.40, 11.35 ]
Total events: 5 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
3 Seroconversion in influenza B antibody
Hsieh 2002 5/9 3/5 100.0 % 0.93 [ 0.37, 2.33 ]
Subtotal (95% CI) 9 5 100.0 % 0.93 [ 0.37, 2.33 ]
Total events: 5 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
0.02 0.1 1 10 50
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Analysis 8.1. Comparison 8 Inactivated poliovirus vaccine early schedule versus late schedule, Outcome 1
4-fold rise in poliovirus antibody titre after first vaccine dose.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 8 Inactivated poliovirus vaccine early schedule versus late schedule
Outcome: 1 4-fold rise in poliovirus antibody titre after first vaccine dose
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in poliovirus type 1 antibody titre
Parkkali 1997 6/22 9/15 100.0 % 0.45 [ 0.20, 1.01 ]
Subtotal (95% CI) 22 15 100.0 % 0.45 [ 0.20, 1.01 ]
Total events: 6 (Intervention), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
2 4-fold rise in poliovirus type 2 antibody titre
Parkkali 1997 5/22 10/15 100.0 % 0.34 [ 0.15, 0.80 ]
Subtotal (95% CI) 22 15 100.0 % 0.34 [ 0.15, 0.80 ]
Total events: 5 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
3 4-fold rise in poliovirus type 3 antibody titre
Parkkali 1997 10/22 12/15 100.0 % 0.57 [ 0.34, 0.96 ]
Subtotal (95% CI) 22 15 100.0 % 0.57 [ 0.34, 0.96 ]
Total events: 10 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
0.1 0.2 0.5 1 2 5 10
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Analysis 8.2. Comparison 8 Inactivated poliovirus vaccine early schedule versus late schedule, Outcome 2
4-fold rise in poliovirus antibody titre after second vaccine dose.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 8 Inactivated poliovirus vaccine early schedule versus late schedule
Outcome: 2 4-fold rise in poliovirus antibody titre after second vaccine dose
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in poliovirus type 1 antibody titre
Parkkali 1997 9/21 13/18 100.0 % 0.59 [ 0.34, 1.05 ]
Subtotal (95% CI) 21 18 100.0 % 0.59 [ 0.34, 1.05 ]
Total events: 9 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
2 4-fold rise in poliovirus type 2 antibody titre
Parkkali 1997 9/21 13/18 100.0 % 0.59 [ 0.34, 1.05 ]
Subtotal (95% CI) 21 18 100.0 % 0.59 [ 0.34, 1.05 ]
Total events: 9 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
3 4-fold rise in poliovirus type 3 antibody titre
Parkkali 1997 13/21 16/18 100.0 % 0.70 [ 0.48, 1.01 ]
Subtotal (95% CI) 21 18 100.0 % 0.70 [ 0.48, 1.01 ]
Total events: 13 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
0.2 0.5 1 2 5
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Analysis 8.3. Comparison 8 Inactivated poliovirus vaccine early schedule versus late schedule, Outcome 3
4-fold rise in poliovirus antibody titre after third vaccine dose.
Review: Vaccines for prophylaxis of viral infections in patients with hematological malignancies
Comparison: 8 Inactivated poliovirus vaccine early schedule versus late schedule
Outcome: 3 4-fold rise in poliovirus antibody titre after third vaccine dose
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 4-fold rise in poliovirus type 1 antibody titre
Parkkali 1997 10/17 14/17 100.0 % 0.71 [ 0.45, 1.13 ]
Subtotal (95% CI) 17 17 100.0 % 0.71 [ 0.45, 1.13 ]
Total events: 10 (Intervention), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 4-fold rise in poliovirus type 2 antibody titre
Parkkali 1997 9/17 13/17 100.0 % 0.69 [ 0.41, 1.16 ]
Subtotal (95% CI) 17 17 100.0 % 0.69 [ 0.41, 1.16 ]
Total events: 9 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 4-fold rise in poliovirus type 3 antibody titre
Parkkali 1997 13/17 16/17 100.0 % 0.81 [ 0.61, 1.09 ]
Subtotal (95% CI) 17 17 100.0 % 0.81 [ 0.61, 1.09 ]
Total events: 13 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
0.2 0.5 1 2 5
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A D D I T I O N A L T A B L E S
Table 1. PRISMA flow chart
Identification Number of records through database searching and other sources = 650
Screening number of records after duplicates removed = 565
Number of records screened = 575
Number of records excluded = 557
Eligibility Number of full text articles assessed for eligibility = 8
Number of full text articles excluded = 0
Included Number of studies included in qualitative and quantitative analyses = 8
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Hematologic Diseases/
2. exp Hematologic Neoplasms/
3. (h?ematolog$ adj1 malignan$).tw,kf,ot.
4. (h?ematolog$ adj1 neoplas$).tw,kf,ot.
5. exp Bone Marrow Diseases/
6. exp Lymphoma/
7. exp Leukemia/
8. hodgkin$.tw,kf,ot.
9. lymphogranulomato$.tw,kf,ot.
10. lymphom$.tw,kf,ot.
11. histiocy$.tw,kf,ot.
12. granulom$.tw,kf,ot.
13. non-hodgkin$.tw,kf,ot.
14. nonhodgkin$.tw,kf,ot.
15. reticulosis.tw,kf,ot.
16. reticulosarcom$.tw,kf,ot.
17. (burkitt$ adj (lymphom$ or tumo?r$)).tw,kf,ot.
18. lymphosarcom$.tw,kf,ot.
19. brill-symmer$.tw,kf,ot.
20. plasm##ytom$.tw,kf,ot.
21. myelom$.tw,kf,ot.
22. sezary.tw,kf,ot.
23. leuk?em$.tw,kf,ot.
24. myelodysplas$.tw,kf,ot.
25. aplast$ an?em$.tw,kf,ot.
26. or/1-25
27. randomized controlled trial.pt.
28. controlled clinical trial.pt.
29. Randomized Controlled Trials/
30. Random Allocation/
31. Double Blind Method/
32. Single Blind Method/
33. or/27-32
34. (Animals not Humans).sh.
35. 33 not 34
36. clinical trial.pt.
37. exp Clinical Trial/
38. (clin$ adj25 trial$).ti,ab.
39. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
40. Placebos/
41. placebo$.ti,ab.
42. random$.ti,ab.
43. Research Design/
44. or/36-43
45. 44 not 34
46. 35 or 45
47. exp Viral Vaccines/
48. vaccines.sh
49. vaccin$.tw, kf, ot.
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50. immunization.sh
51. prophylaxis.tw,kf,ot.
52. or/47-51
53. exp Chickenpox/
54. exp Varicellovirus/
55. exp Herpes Zoster/
56. exp Influenza/
57. exp Measles/
58. exp Mumps/
59. exp Rubella/
60. exp Poliomyelitis/
61. exp Hepatitis/
62. exp Rotavirus/
63. exp Yellow fever/
64. exp Rabies/
65. exp Encephalitis/
66. varicell$.tw,kf,ot.
67. chickenpox.tw,kf,ot.
68. zoster.tw,kf,ot.
69. flu.tw,kf,ot.
70. measles.tw,kf,ot.
71. mumps.tw,kf,ot.
72. rubella.tw,kf,ot.
73. MMR.tw,kf,ot.
74. polio$.tw,kf,ot.
75. hepatitis.tw,kf,ot.
76. rotavir$.tw,kf,ot.
77. (yellow adj1 fever).tw,kf,ot.
78. rabies.tw,kf,ot.
79. encephalitis.tw,kf,ot.
80. Or/53-79
81. 26 and 46 and 52 and 80
Appendix 2. EMBASE search strategy
1. Hematologic disease/
2. Hematologic neoplasm/
3. Bone marrow disease/
4. Lymphoma/
5. Leukemia/
6. hematolog$ malignan$.mp
7. hematolog$ neoplas$.mp
8. hodgkin$.mp
9. lymphogranulomato$.mp
10. lymphom$.mp
11. histiocy$.mp
12. granulom$.mp
13. non-hodgkin$.mp
14. nonhodgkin$.mp
15. reticulosis.mp
16. reticulosarcom$.mp
17. (burkitt$ lymphom$ or burkitt$ tumor$).mp
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18. lymphosarcom$.mp
19. brill-symmer$.mp
20. plasmacytom$.mp
21. myelom$.mp
22. sezary.mp
23. leukem$.mp
24. myelodysplas$.mp
25. aplast$ anem$.mp
26. or/1-25
27. Controlled Clinical Trial/
28. Randomized Controlled Trial/
29. Double Blind Method/
30. Single Blind Method/
31. Randomization/
32. Placebo/
33. blind$.mp.
34. placebo$.mp.
35. prospectiv$.mp.
36. random$.mp.
37. ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp.
38. (randomized controlled trial$ or randomised controlled trial$).mp.
39. controlled clinical trial$.mp.
40. or/27-39
41. Human/
42. Nonhuman/
43. Animal/
44. Animal Experiment/
45. or/42-44
46. 45 not 41
47. 40 not 46
48. Viral vaccine/
49. vaccin$.mp
50. (immuniz$ or immunis$).mp
51. prophyla$.mp
52. or/48-51
53. Chickenpox/
54. Varicellovirus/
55. Herpes Zoster/
56. Influenza/
57. Measles/
58. Mumps/
59. Rubella/
60. Poliomyelitis/
61. Hepatitis/
62. Rotavirus/
63. Yellow fever/
64. Rabies/
65. Encephalitis/
66. varicell$.mp
67. chickenpox.mp
68. zoster.mp
69. flu.mp
70. measles.mp
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71. mumps.mp
72. rubella.mp
73. MMR.mp
74. polio$.mp
75. hepatitis.mp
76. rotavir$.mp
77. yellow fever.mp
78. rabies.mp
79. encephalitis.mp
80. or/53-79
81. 26 and 47 and 52 and 80
Appendix 3. CINAHL search strategy
(hematolog*malignan* or hematolog* neoplas* or lymphom* or leukem* or hodgkin* or lymphogranulomato* or histiocy* or granulom*
or non-hodgkin* or nonhodgkin* or reticulosis or reticulosarcom* or lymphosarcom* or brill-symmer* or plasmacytom* or myelom*
or sezary or myelodysplas* or aplastic anem*) and (randomized controlled trial or controlled clinical trial or random* or double blind
or single blind or treble blind or triple blind or placebo*) and (vaccin* or immuniz* or immunis* or prophyla*) and (chickenpox or
varicell* or zoster or influenza or flu or measles or mumps or rubella or MMR or polio* or hepatitis or rotavir* or yellow fever or rabies
or encephalitis)
Appendix 4. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
(hematolog*malignan* or hematolog* neoplas* or lymphom* or leukem* or hodgkin* or lymphogranulomato* or histiocy* or granulom*
or non-hodgkin* or nonhodgkin* or reticulosis or reticulosarcom* or lymphosarcom* or brill-symmer* or plasmacytom* or myelom*
or sezary or myelodysplas* or aplastic anem*) and (chickenpox or varicell* or zoster or influenza or flu or measles or mumps or rubella
or MMR or polio* or hepatitis or rotavir* or yellow fever or rabies or encephalitis)
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